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ABSTRACT
With an estimated 5 million people suffering from valve disease in the

United, valve disease is currently the leading cause of cardiovascular disease.1 Each
year, between 80,000 and 85,000 aortic valve replacements are performed in order
to treat the stenotic heart valves. Despite this being a worldwide epidemic, the

current valve replacement options that are on the market have distinct limitations.
Furthermore, a viable alternative does not exist for the patients that are not

candidates for the current treatment methods. Our proposed solution to this

epidemic is to create a highly viable injectable scaffold that would allow for the

minimally invasive delivery of human adipose-derived stem cells (hADSCs), as well
as to provide necessary biological cues for growth and remodeling to the scaffold.
A process was created to create a hydrogel derived from decellularized

porcine aortic cusp tissue. The aortic cusp was solubilized using an acid-pepsin

solution, neutralized and reformed as a hydrogel structure. This processing was

analyzed for effectiveness of decellularization, retention of the extracellular matrix
components, scaffold architecture, and cell interaction and viability.

Histology showed proper decellularization while maintaining the

components of the extracellular matrix throughout the fabrication process, collagen
content analysis provided further evidence of this. Quantitative analysis of H&E

sections revealed a highly porous scaffold, conducive to cell migration. Rheological
ii

studies revealed shear thinning properties that is advantageous for the ability of the
scaffold to be injected. A Live/Dead assay of the scaffold showed an extremely

viable scaffold in static conditions, as well as a tendency of the cells to contract and
remodel the hydrogel.

Present studies have optimized the technique for creation of the hydrogel,

characterized the biological and physical properties of the scaffold, and determined
the viability of the scaffold for seeding of hADSCs. These aortic cusp-derived

scaffolds provide an environment that mimics the aortic cusp ECM. This research

will advance cardiovascular tissue engineering and further aid in the search for the
ideal tissue engineered heart valve.
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CHAPTER 1: INTRODUCTION
AND BACKGROUND

1

1.1 Structure and components of the cardiovascular system
The cardiovascular system serves as a closed system that circulates blood

throughout the body in order to deliver nutrients and oxygen to the body. This

system consists of two circuits, the pulmonary circuit and the systemic system. The
pulmonary circuit is responsible for oxygenating the blood and eliminating the

carbon dioxide from the blood. The systemic circuit is responsible for delivering the
oxygenated blood and nutrients to the body, as well as to remove the waste from

those cells. These circuits work together to keep the cells from becoming deprived
of the necessary nutrients to survive. At the center of this system is the muscular
pump in charge of pushing the blood throughout the system, known as the heart.
The heart works through continuous contractions and relaxations, known as the
cardiac cycle. The heart is a very hard working organ that is responsible for
pumping 7,000 liters of blood through the system, every single day.2
1.1.1 Pericardium and the tissue layers of the wall

The protection of the heart is charged to the pericardial sac, which covers the

heart with three layers of pericardium: the fibrous pericardium, parietal

pericardium, and the visceral pericardium. The outermost layer of the pericardial
sac, the fibrous pericardium, is responsible for providing a tough and protective
layer of dense connective tissue. This layer is attached to the diaphragm, the

vertebral column, and the large blood vessels that emerge from the heart2. The
other two layers, the visceral and parietal pericardium, form a double layered

serous membrane. Between these two layers is a space called the pericardial cavity,
2

containing serous fluid. This fluid is secreted by the membranes of the pericardial
cavity in order to reduce the amount of friction between the pericardium and the
heart. The innermost layer, the visceral pericardium, corresponds to the
epicardium, which is the outer layer to the wall of the heart.3

The wall of heart is comprised of three different layers of tissue: the

epicardium, myocardium, and endocardium. The epicardium is the outermost layer
of the wall, which is connected to the visceral pericardium. This layer of tissue

reduces the amount of friction that the heart is subjected to, which helps contribute
to protecting of the heart. This layer consists of connective tissue that includes

capillaries for both blood and lymph, as well as nerve fibers. The next layer of the

wall is the myocardium, which is made up of cardiac muscle tissue that contracts to
pump blood out of the chambers. This layer consists both of the muscle fibers used
to contract the chambers and the connective tissue that allows blood and lymph

capillaries to run through the muscle fibers. The innermost layer of the wall is the
endocardium, which is comprised of connective tissue, epithelial tissue, blood

vessels and Purkinje fibers. This layer lines all the chambers and covers the heart
valves and other structures of the heart. The anatomy of the wall of the heart, as
well as the pericardial sac, is pictured below in Figure 1.2

3

Figure 1: The three layers of the wall of the heart and the three layers
of the pericardial sac.2

1.1.2 Valves and chambers of the heart
There are four internal cavities that divide the heart into sections, known as

chambers. There are two chambers on the right and two chambers on the left, each
of which lead to different parts of the cardiovascular system. The upper chambers

of the heart are known as the atria, which are thin walled and accept the blood that
is returning to the heart through the cardiovascular system. The lower chambers,
are known as the ventricles, are responsible for forcing the blood inside the

chambers of the heart back out into the arteries. The right atrium is responsible for
receiving blood from the superior and inferior vena cava, which returns blood from
the body that is low in oxygen. The left atrium is responsible for receiving

oxygenated blood from the pulmonary veins, which returns the blood from the

lungs. The left ventricle is specifically responsible for receiving the blood from the

left atrium and forcing the blood to all other parts of the body. The right ventricle is
4

responsible for receiving the blood from the right atrium and pumping it out to the
Due to the fact that the left ventricle has to push the blood a much greater distance
than the right ventricle, the walls of the left ventricle are therefore much more

muscular in order to be capable of moving the blood the required distance. The

layout of the chambers of the heart, as well as how they interact with the rest of the
cardiovascular system, is shown in Figure 2 below.3

Figure 2: Anatomy of the Chambers and Valves of the Heart3

The chambers of the heart are divided by four valves, which function as

gateways for the blood to be pumped through. These valves allow the blood to

move from one side to the other without backflow occurring. Similar to there being
two types of chambers, there are also two types of valves. One of the types of valve
is called the atrioventricular valve and as its name suggests, these two valves

separate their respective atria and ventricle. These valves open when the blood

pressure is greater on the side of the atria and the valve will close when the blood

pressure is greater on the side of the ventricle. The tricuspid valve covers the large
5

orifice between the right atria and right ventricle with its three leaflets structure
and the mitral valve covers the large orifice between the left atrium and left

ventricle with its bi-leaflet structure. These valves also have chordae tendineae, or
fibrous tissue strings, that prevent the valves from swinging backwards into the
atrium. The second type of valves are the semilunar valves, the name of which

comes from the half-moon shape of the cusps of the valve. The two valves that make
up this category are the pulmonary valve, which covers the entrance to the

pulmonary trunk, and the aortic valve, which covers the entrance to the aorta.

These valves open upon contraction of the ventricular wall to allow blood to rush
out of the heart and into the rest of the system. These valves close upon the

relaxation of the ventricular wall to prevent backflow into the ventricles. The
anatomy of these four valves are shown in Figure 3 below.2

Figure 3: Superior view of the heart depicting all four heart valves.2
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1.1.3 Blood vessels and blood flow
To understand the need for the complexity of the cardiovascular system, the

route, purpose, and interactions of the blood with the rest of the body must be fully
understood. Deoxygenated blood travels enters the heart, leaving the venae cava

and coronary sinus and enters the right atrium. The blood then passes through the
tricuspid valve into the right ventricle, which then enters the pulmonary circuit

upon contraction of the right ventricle and opening of the pulmonary valve. The

blood travels to lungs through the pulmonary arteries in which the oxygen exchange

occurs in the capillaries of the alveoli. Once the gas exchange occurs, the oxygenated
blood returns to the heart through the pulmonary veins, enters the left atrium, then
passes into the left ventricle through the mitral valve. The blood is then pushed

through the aortic valve upon ventricular contraction and into the systemic circuit.
This circuit is responsible for delivering the nutrients and gas that the newly

oxygenated blood into the tissue cells through the thinly walled capillaries. The

deoxygenated blood then returns through the systemic veins and into right atrium,
completing the entire circuit. The entirety of this process can be seen in Figure 4.2
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Figure 4: Diagram of the path blood takes throughout the body, picturing the both the pulmonary and
systemic circuit.2

Due to the blood traveling through the systemic circuit having a much larger

distance to travel, the aortic and mitral valves is subjected to a larger amount of

shear stress than the pulmonary and tricuspid valves. This increase in shear stress
contributes to the higher incidence of disease in the aortic and mitral valves.
1.2 Anatomy and physiology of the aortic valve

In order to design an effective replacement for a diseased aortic valve, the

entirety of the aortic valvar complex should be completely understood4. This

complex consists of all the components of the aortic root and the ascending aorta.
The aortic root is the lower part of the aortic valvar complex that contains the

leaflets of the valve, the sinotubular junction, the annulus, the inter-leaflet triangles,

and the Sinus of Valsalva. The anatomy of the aortic valvar complex is shown below
in Figure 5.
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Figure 5: Diagram of the path blood takes throughout the body, picturing the both the pulmonary and
systemic circuit.5

The normal aortic valve has a tri-leaflet structure and the interaction

between these leaflets is responsible for whether or not the valve is functioning

properly. These leaflets work together to form a boundary between the ascending
aorta and the left ventricle and acts as a hemodynamic junction. This tri-leaflet

design is optimized for a low resistance opening and high level of efficiency in the
cardiovascular system.5 This tri-leaflet structure is very important to the

functionality of the valve, which can be seen with the pathology of the bicuspid

defect in those with congenital defects. Recreating the functionality of the tri-leaflet

stricture when trying to create a working valve replacement is imperative creating a
permanent solution to a diseased valve.

Every one of these components works in harmony in order to create a

functioning complex that pumps oxygenated blood throughout the body. When an

9

aortic valve becomes diseased it can be a result of the valve not functioning

properly, but can also be caused by dysfunction in the other parts of the complex.
1.2.1 Tissue layers of the aortic valve

While the structure of the aortic root complex, the structure of the leaflets of

the aortic valve are also extremely important to the functionality of the valve. The

importance of the structure is at both a macro- and a micro-level, as seen in Figure
6. The three layers are known as the fibrosa, spongiosa, and ventricularis.

Figure 6:Cross section of an aortic cusp, showing the three layers: fibrosa, spongiosa, and ventricularis.6

These layers contain different components that ultimately decide the

properties of the valve.7 The ventricularis is the layer located on the left ventricular
side of the valve. This layer of the valve is made up of a layer of elastin fibers with

are arranged radially to reduce the strain caused by the inflow of blood. The middle
layer, known as the spongiosa, is made up of glycosaminoglycans (GAGs). These

GAGs are long, unbranched polysaccharides which help to lubricate the ventricularis
10

and fibrosa layers, helping to cut down on the shear and deformation that the

cardiac cycle causes. The layer on the aorta side of the valve is called the fibrosa.
This layer is made of two types of fibrillar collagen (Type I and Type III), which

serves as the load-bearing layer of the leaflet. This is done with a circumferential
formation of these collagen fibers. Each of the layers also has layers of valve
endothelial cells (VECs) lining the outside of the leaflets and valve in valve

interstitial cells (VICs). The endothelial lining of the leaflets help to maintain

homeostasis of the valves. This is done through a variety of mechanisms including

regulating permeability, paracrine signaling, and inflammatory cell adhesion7. The
valve interstitial cells of each layer serve as the source of components for the

extracellular matrix of the tissue. These components consist of collagen, elastin, and

GAGs and they provide the necessary strength and elasticity for a functioning leaflet,
as seen in Figure 7.

Figure 7: Three layers of the aortic valve: the fibrosa, spongiosa, and ventricularis. Each layer is lined
with valve interstitial cells.7
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1.2.2 Importance of the Valve Interstial Cells and Valve Endothelial Cells
As discussed in the previous section, VICs and VECs both play an enormous

role in the biological function of the aortic valve. The interstitial cells are of

particular interest because they are the most common cell present in the valve.8

This cell type a mesenchymal cell type and therefore can be differentiated into the
different phenotypes of VICs from the embryonic mesenchymal cell type. The five

different phenotypes of VICs are the embryonic progenitor mesenchymal stem cells,
quiescent VICs, activated VICs, progenitor VICs and osteoblastic VICs. Each of these
different phenotypes serve a different function and all of them can be found in the
leaflet of the heart valve. Because of the diversity of the functions of the different
phenotypes, it is important that when trying to utilize these cells in tissue

engineered aortic valves, the correct phenotype is used in order to utilize the
correct function and give the most functional valve. The quiescent VICs are

responsible for maintaining the valve’s structure and function, as well as to inhibit

angiogenesis in the valve. The activated VICs function as the repairmen of the valve,
working to repair and remodel diseased valves. These cells respond to the

abnormal hemodynamic or mechanical conditions consistent with pathological

valves and work to remodel the extracellular matrix of the leaflet. The progenitor
VICs are a recently discovered phenotype of VICs, thought to be derived from
hematopoietic cells during a time of injury, meaning they also respond to the

degenerated and diseased tissue and help to remodel the cells. This pathway of

differentiation from a separate cell line is particularly interesting, as these cells have
12

a similar function to that of the activated VICs, but only arise in the presence of

pathogenic valves and have different markers than the activated VICs. The last

phenotype of adult VICs is osteoblastic VICs. This last phenotype is differentiated
from the quiescent VICs, but unlike those cells, the osteoblastic has a role in

calcification of the heart valve and the degradation of the ECM. This particular
phenotype gets its name from its function, which is very similar to that of the

osteoblasts that remodel the bone matrix. This cell is undesirable in the leaflets

because it can lead to a stenotic valve through the calcification of both a native valve
and a tissue engineered valve, so steps must be taken to inhibit this differentiation

process in a TEV. A number of methods to inhibit the calcification of the osteoblastic
VICs such as the addition of an anti-apoptic agent ZVAD-FMK or the use of matrix
metalloproteinases (MMPs) to regulate calcification and ECM degradation in the

leaflets, but ultimately very little is known about the inhibition of these osteoblastic
VICs. More research should be done with this phenotype in order to be able to

effectively inhibit the differentiation and function that leads to stenotic heart valves.
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Figure 8: An organizational chart of the phenotypes of VICs, depicting both the differentiation pathway
and the function of each phenotype.8

1.3 Pathology of the aortic valve

1.3.1 Prevalence of aortic valve disease
Cardiovascular disease (CVD) is one of the most common causes of death in

the world, killing 678,000 people in 2010 in the United States alone, 1.68 million
worldwide.9 The most frequent subtype of CVD is an aortic valve disease (AVD),

which can be diagnosed by a few different characteristics. One of the more common
type of AVD is a congenital defect, or one that is developed at birth, known as the

bicuspid aortic valve (BAV). BAV is a defect in which the affected party effectively
only has two leaflets of the aortic valve, either by partial or total fusion of two

leaflets. This defect is estimated to be present in three million people across the

world and is also estimated to occur in 1.3% of new born infants.10 Because this

defect of the aortic valve is congenital, the incidence is not affected by age, as it is

acquired at birth. In addition to a congenital defect of the aortic valve, AVD also can
14

include aortic valve stenosis, which is present in about 54,000 people in the United
States. This disease is found more frequently in older patients, as it is usually a
result of calcium build up on the leaflets of the valve over time.
1.3.2 Pathology of common aortic valve diseases

There are many risk factors associated with the development of a valve

disease, many of which are also associated with the myriad of cardiac diseases that
can lead to cardiac events such as infarctions and cardiac failure. Advanced

hypertensive, diabetic individuals, or individuals that have been exposed to certain
infections, such as the bacteria associated with rheumatic fever, are some factors

that put individuals at a higher risk for developing a heart valve disease11. Once the

valve begins to function abnormally, it is characterized by an irregular heartbeat, or
a murmur, and can usually be heard before any other symptoms occur in patients.

This murmur of the heart is usually a sign that the valve is becoming stenotic, or is
unable to open fully and properly, obstructing blood flow12.

In the pathogenesis of these diseased heart valves, there are a few pathways

that the valve can take to reach a state of dysfunction. An advanced bacterial

infection caused by either the staphylococcus bacteria or syphilis could cause an

inflammation and thickening of the valve, but only in the event that the valve had

already been previously inflamed by another event, such as a myocardial infarction
(MI).13 The valve undergoes a thrombotic effect through the collagen of the valve
attracting platelets to the surface, resulting in thrombus formation, and the

resultant endothelial damage to the valve can be permanent. This condition is called
15

infective endocarditis, though the advent of penicillin and the decline of rheumatic

fever have rendered this pathway of disease a thing of the past in the modern world.
1.3.3 Calcification of the aortic valve

Another pathway of valvular degeneration is by way of the calcification of the

heart valves, which is limited to the left side of the heart’s valves, the aortic and the
mitral valves. This calcification is one of the main causes for stenosis of the valves,
due to the calcium deposits causing a narrowing and stiffness of the valve13. This

degenerative calcification develops in the cusp fibrosa tissue and results in calcific

aortic valve disease (CAVD). The calcium deposits on the surface of the cusps of the
valve, which forms masses of calcium build up and stiffens and thickens the valve.

The valve will eventually accumulate enough calcium on the surface that it loses its
mobility, becoming stenotic, as seen in Figure 9.

Figure 9: A comparison of a healthy aortic heart valve and a stenotic valve caused by calcification.14

The calcium deposits can also become so large that they project into the

aortic sinuses, which can result in further blocking of blood flow. Calcium build up
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usually occurs over time, and the sites of the initial binding suggest that the

repeated damage from flexing may be the initiating factor13. Abnormal valves, such

as congenital bicuspid aortic valves, are associated with a higher risk of calcification,
due to its abnormal anatomy and function.

The other abnormal valve function that can result in complications, aside

from stenosis, is valve regurgitation. Regurgitation is caused by incompetence in

the valve in which the valve does not close fully, allowing back flow of blood into the
ventricle. Regurgitation, like stenosis, can be caused by calcium build up or from a
congenital defect in the valve. Patients who have regurgitation usually tolerate it
well and may never need to seek treatment, but they may eventually experience

ventricular hypertrophy13. Patients who have diseased heart valves can relate their
symptoms to that of the early signs of heart failure, which can also be an end result

of a diseased heart valve. Thus, if left untreated, a diseased heart valve can be a fatal
condition. Therefore, treatments should be sought to replace the diseased valve
before late stage heart failure begin to occur.
1.4 Current valve treatment options

Surgical replacement of a diseased aortic valve Patients who have diseased

heart valves can relate their symptoms to that of the early signs of heart failure,

which can also be an end result of a diseased heart valve. Thus, if left untreated, a
diseased heart valve can be a fatal condition. Therefore, treatments should be

sought to replace the diseased valve before late stage heart failure begin to occur.
There are two kinds of procedures that physicians use to repair or replace the
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diseased valves. Physicians have the choice between using a minimally invasive
procedure, such as a balloon valvuloplasty, to repair the valve and a surgical

procedure to replace the valve entirely with a mechanical or bioprosthetic valve.
1.4.1 Minimally invasive repair of diseased valves

Stenosis of the valves can be diagnosed rather easily through the use of a

stethoscope in the presence of a murmur of the valve. Once the diseased valve is
discovered, it can be evaluated and monitored through the use of an

echocardiogram (echo). Once the diseased valve reaches a point of concern for the

physician, the valve can possibly be repaired in one of the few following ways, if the
valve is not fully dysfunctional.

The cardiologist can use cardiac catheterization to perform balloon

valvuloplasty in order to repair a diseased valve. The balloon valvuloplasty is a

comparatively simple procedure to perform, seen in Figure 10. This method is

appealing due to its minimal invasive nature and thus the minimal recovery time

and stress it puts on the patients. Unfortunately, this balloon valvuloplasty is not

very effective in the long term, often resulting in restenosis of the aortic valve within
a year of the procedure15, but has been shown to be more effective in the mitral
valve stenosis. Thus, the balloon valvuloplasty should be seen as a method to

relieve symptoms, but not as a permanent resolution to the underlying disease.

18

Figure 10: Balloon Valvuloplasty.15

1.4.2 Surgical replacement of diseased valves
In the event the stenosis of the valve becomes advanced and symptoms

become dangerous, the cardiologist may elect to proceed with a surgical

replacement of the stenotic valve. There are two major types of heart valve

replacements: mechanical valves and bioprosthetic valves. Each type of offers its
own advantages and disadvantages, and thus it is not always clear which type is
more suitable for the treatment of the patient with valve disease. This choice

involves a balance of the inherent advantages and disadvantages that each valve
replacement type has to offer.

Mechanical valves are well known to be extremely durable, due to their

excellent mechanical properties, thus decreasing the need for a future surgery to
replace due to wearing out16. With that inherent advantage comes some major

disadvantages though; the mechanical valves are thrombogenic, which means that
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the patient will need to be on anticoagulants for the rest of their life and will be at an
increased risk of hemorrhaging.

The bioprosthetic valve offers the patient a non‐thrombogenic alternative to

the mechanical valve, as it is more biocompatible16. Another advantage that the

bioprosthetic heart valve offers over the mechanical valve is its ability to be utilized
in a newer surgical method, known as the transcatheter valve replacement (TVR).
This procedure allows for the valve replacement to be surgically put into place
through a catheter, and therefore is minimally invasive and offers all of the

advantages of a minimally invasive procedure. This procedure is most commonly

performed on aortic stenosis, and is known as TAVR in this case. This is procedure

is performed fairly similar to the cardiac catheterization described prior, but on the
end of the catheter there is a valve that has been engineered to push the old valve
out and replace it, either by balloon or by spring, shown in Figure 11.

Figure 11: Transcatheter aortic valve replacement (TAVR) procedure17
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Again, with this advantage comes a distinct disadvantage, as the

bioprosthetic valves only last about 10-15 years, due to the material undergoing

structural deterioration16. Part of this structural deterioration that comes with the

bioprosthetic heart valves is its tendency to calcify, or re-calcify in the cases of CAVD
patients, which leads to the restenosis of the valve and thus the need for another

valve replacement. This calcification of the bioprosthetic heart valves is a main area
of concern for current tissue engineering, in order to engineer a bioprosthetic
replacement valve that is both durable and non-thrombogenic.
1.4.3 Limitations of the current valve replacements

Calcification of the implant is not a problem that only affects bioprosthetic

heart valves, but one that has been affecting a variety of cardiovascular implants,
such as the aortic homograft and tri-leaflet polymeric valve prosthesis. 18 This

pathological pathway has caused the dysfunction of these different medical devices
prematurely through the buildup and mineralization of calcium phosphate

molecules on the surface. This calcification can lead to the dysfunction of these

replacements by either causing mechanical dysfunction (a failure in opening and

closing), an obstruction of the vasculature, or the calcium deposits breaking off or

causing an embolism.18 There are many steps in the pathology of the calcification of

a bioprosthetic tissue replacement, which lead to the degenerative nature of the

valve, shown in Figure 12.19 This process was initially thought to be unregulated,

but it is now thought to be a regulated event through the use, and loss of function of,
mineralization inhibitors. This physiological process is similar to that of the
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mineralization of bone. This calcification deposition and degradation occurs in the

replacements due to the calcium in the blood binding to the mechanically damaged
cell fragments of the bioprosthetic tissue. This calcium deposition is especially
problematic for the bioprosthetic tissue due to the chemical cross-linking with

glutaraldehyde fixation. This fixation disables the calcium pump in the cells, which
in healthy cells allows calcium ions to be pumped out of the ability of cells in the
tissue to pump calcium out of the cells. The calcium in the membranes will then

bind to the phosphate, which results in the buildup, and eventual enlargement of

calcium crystal molecules. This is crystal growth ultimately stiffens and weakens
the tissue until dysfunction or failure begins to occur.

Figure 12: The hypothetical model of how calcification occurs in bioprosthetic valves..19
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Some further regulatory investigations suggest that this calcification may be

regulated by noncollagenous matrix proteins, such as osteopontin, osteonectin, and
osteocalcin.19 Osteopontin is an active calcium binding phosphoprotein that has a

high affinity to hydroxyapatite, a key component in bone formation. This and highdensity cholesterol (HDL) function as inhibitors for calcium binding. Other factors
that have been demonstrated to have a regulatory role in calcification of

bioprosthetic heart valves include TGF‐α, and tenascin‐C. Evidence suggests that

hypercholerolemia may play a role as a risk factor, due to the large amount of low-‐

density cholesterol (LDL) in the blood causing inflammation. The pathway for

vascular cell calcification was mimicked in genetic studies in transgenic mice using a
metalloproteinases (MGP) gene knock out, or inactivation of the osteopontin gene,
and it was observed that severe calcification of the blood vessels occurs. This

confirms that the osteopontin gene is essential to the regulation of mineralization,
and also that calcification can be inhibited through the inhibition of matrix
remodeling metalloproteinases.
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Figure 13: (A,B)H&E stains of calcified leaflets. (C)Masson trichrome stain of a non-calcified leaflet.20

Another potential pathway of calcification that has been postulated is that of

the inflammatory and immune processes upon valve replacement19. This pathway
has gained some ground due to antibodies specific to valve components being
detected in some patients with valve dysfunction and failed tissue having

mononuclear inflammation. Although these two components provide some a hint
that they play a role in the calcification process, there have been studies in nude
mice (T-cell function knocked out) that still exhibited calcification morphology,

which points to the fact that the immune and inflammation responses may be a

secondary response to the valve damage caused by calcification, rather than the
causal factors of failure.19

1.4.4 The ideal engineered valve replacement
Tissue engineering is a field that deals with the creation of tissue based

“scaffolds” in order to replace or repair a diseased structure in the body. This
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process is can be done in a number of different ways, but the ultimate goal is to

create a scaffold that has the same or similar mechanical, chemical, and structural
properties of the original organ or tissue.21 In order to create the ideal functional

tissue-engineered scaffold the following objectives must be met, as proposed by the
leaders in the musculoskeletal field:22

1.

Define the functional success of the tissue before implementing

3.

Establish design requirements of the scaffold

2.
4.
5.
6.

Understand biomechanical properties of both the engineered and native tissue
Understand microenvironment of the cells within the scaffolds
Control cellular differentiation through biophysical stimuli
Provide a permanent solution as a treatment

These objectives must be met for the construct to be considered a viable

option in implementation. One method of creating the ideal scaffold has be

proposed to be achieved by using biological scaffolds, such as repurposing a piece of
animal tissue that has been decellularized and then recellularized with a cell type

that have no cytotoxicity and illicit no immunologic response. These scaffolds

would allow for the proper biochemical and mechanical signaling for the culture of

the cells that are seeded onto the scaffold because they are derived from the original
tissue type. Other methods include creating a scaffold from a polymer, synthetic or
natural, to mimic the structure of the original tissue.

The ideal tissue engineered valve would provide three components that

would work together to replace or repair the diseased tissue. These three
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components are the physical structure of the tissue, the cellular components, and
the chemical properties and these components would be as similar as possible to

that of the native tissue before disease. In addition to these three components, the
ideal tissue engineered valve should not be cytotoxic, not illicit an immunologic
response, have a small diffusion barrier to allow nutrients to diffuse into the
scaffolds, and the control of the degradation time of the scaffold.21 This last

characteristic is very important because it allows for the proper amount of time for
integration of the scaffold at both the cellular and tissue levels.
1.4.5 Adipose stem cells in tissue engineering

Tissue engineering, or regenerative medicine, relies on many different

variables in order to repair or replace a damaged organ. Despite the recent

advances in material science, which have resulted in the ability to fabricate fully
biocompatible scaffolds that allow for cell infiltration and angiogenesis, a

challenging aspect of this multidisciplinary endeavor remains to be the availability

and utilization of stem cells. In order to find the ideal stem cell, the desired stem cell
should meet the following guidelines, described by Gimble et al. The stem cells must

be found in abundance, acquired with a minimally invasive procedure, have multiple
cell lines that the cell can differentiate into, is able to be transplanted safely into
both autologous and allogenic hosts, and can be manufactured within the Good

Manufacturing Practice guidelines23. These guidelines rules out most cell types, due

to their inability to be harvested efficiently, but a particular cell type stands out as
one that falls within the guidelines described above. This cell type is the adipose
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derived stem cell and they are isolated through the tissue harvested from

liposuction, meaning there is plenty of available tissue due to the increasing

popularity of the liposuction procedure. These cells are also capable of being
differentiated into many different cell lines, as seen in Figure 14 below.

Figure 14: Possible lineages of adipose-derived stem cells.24

One of the major aims of tissue engineered scaffolds is to create a scaffold

that is fully populated with cells prior to their implantation. The problem with the

seeding of these scaffolds is that the cells like to adhere to the surface of the tissue,
but usually cannot penetrate inside the extracellular matrix. There are a few

different techniques that have been developed in tissue engineering to try and
uniformly seed the scaffold with cells throughout its entire thickness.
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1.4.6 Limitations and challenges in valve tissue engineering
Obviously, there are some strict guidelines and regulations that come with

the design of a tissue engineered heart valve. But in today’s current prosthesis

regime, there is no real “gold-standard” for the replacement valve, due to either the
mechanical or the bioprosthetic valve coming at a significant cost, the increase of

complications. Thus the ultimate challenge in any tissue-engineering field, and it holds
true for the fabrication of bioprosthetic valves, is to create that “gold-standard” with

the least amount of complications. There is a limitation, therefore, to the materials
that are most likely to be durable and sustainable inside the body, while
maintaining a non-thrombogenic effect.

One of the biggest challenges is presented not by the valve itself, but by the

exposed aortic wall. The aortic wall is much harder to treat with anti-calcification

methods, due to the differing effects of the pretreatment methods19. Thus a material
must be found that can be effective on both the aortic wall and the valve itself, or a
combination therapy must be utilized to gain the beneficial effects necessary to

make the new bioprosthetic valve a viable option to the alternative that is already
on the market.

Another challenge that comes inherently with working with the heart valve is

that, in order to gain valuable and meaningful data, a 15 to 20 year clinical study
must be completed before any conclusions can be drawn, and therefore the

bioprosthetic valves that are on the market are between 15 to 20 years behind the

current research. There is recent literature that has shown a recent shift to the
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study of hydrogels. This research is in its early stages, and therefore there are very
little clinical results to draw conclusions from the hydrogel paradigm at this time,

but they do offer a promising and exciting future for the of valve tissue engineering,
specifically when it comes to the inhibition of calcification.

The future of current research in bioprosthetic heart valve replacements

seems to be headed in the direction of modifications of the current bioprosthetic

model. These modifications must first be tested in clinical settings, which takes a

large amount of time to research. Once the calcification of the modifications have
been sufficiently researched, there seems to be a shift towards the use a multi-

material valve paradigm, possibly coupled with the use of another anti-calcification
therapy in order to maintain the structural and mechanical properties necessary to

avoid primary failure of the bioprosthetic valve replacement, while still eradicating

the need to replace the valve in 10 to 15 years due to the degradation and restenosis
from calcium deposition.

1.5 Hydrogels in tissue engineering
Hydrogels have been utilized in a variety of medical applications over the last

60 year. The first documented use of a synthetic hydrogel was in 1954, when

Wichterle and Lim developed a soft contact lens.25 Sense then, hydrogels have been
applied to plenty of different technologies across multiple disciplines, such as
hygiene products, agriculture, food additives, and biomedical applications.

Hydrogels are becoming especially popular when it comes to designing

scaffolds in tissue engineering and regenerative medicine for a variety of reasons.
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These hydrogels are capable of replicating the structure of the extracellular matrix
of the original tissue. The hydrogels are also appealing due to their ability to be

synthesized in mild conditions and therefore they are relatively easily to fabricate.

The cause for the shift focus to hydrogels as scaffolds in the tissue engineering field

is due to the ease of fabrication and the minimally invasive nature of the application
of these hydrogels. Some of the major uses for the hydrogels include drug delivery,
growth factor delivery, and cell delivery to the site of injury. These scaffolds can

either be created from natural or synthetic materials to try and mimic the native
tissue.

The design and material selection for a tissue engineered scaffold is

dependent on the desired application of that scaffold. The goal of most of these
scaffold materials is to replicate a natural structure in the body, such as the

extracellular matrix, in order to replicate the structural and mechanical properties
of the native tissue that is being replaced. Unfortunately, the solid scaffold

structures are usually synthesized in an environment that results in an acellular

scaffold, either through the decellularization of a natural construct or the fabrication
of a polymer structure in severe conditions. This factor makes the incorporation of

viable cells onto the scaffold exceedingly difficult to achieve. In order to achieve the

seeding of cells onto the desired scaffold, there has been a shift to the use of a highly
hydrated scaffold, known as a hydrogel. These hydrogel scaffolds can be composed
of either natural-derived materials, synthetically derived materials, or a composite
hydrogel that is composed of both natural and synthetic materials. The hydrogels
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have many advantages over the traditional scaffold due to the properties gained
through their highly hydrated structure and mild conditions during their

synthetization method, while potentially maintaining similar mechanical and
structural properties to that of tissue and the extracellular matrix.

Hydrogels are three dimensional hydrophilic polymer constructs that have

been imbibed with large amounts of fluids and crosslinked, which allow the

hydrophilic hydrogel to be water-swellable without becoming water soluble. These

hydrogels most closely resemble soft tissue and are usually made up of components

that are either similar to or derived from native tissue components, such as the ECM.
1.5.1 Current hydrogels in tissue engineering

The strategies for creating a hydrogel for tissue engineering applications

vary based on the both the desired application and the type of materials available.
The desired material is dependent on the type of properties that the target tissue
require. Materials that are commonly used for scaffolds, while FDA approved

mechanically strong, can be hydrophobic and created in very harsh conditions

making the incorporation of cells into the scaffold impossible. However, hydrogels
can be synthesized in much milder conditions and therefore can serve as a great

alternative to traditional scaffolds. These hydrogels, both natural and synthetic, can

take the place of the commonly derived scaffold materials when the entrapment and
incorporation of viable cells are required. Hydrogels are made up of overly hydrated
polymers, resulting from the incorporation of hydrophilic polymer chains into the

scaffold. This leads to hydrophilic scaffold materials and in turn the incorporation
31

of viable cells into the scaffold becomes possible. There are many different types of

hydrophilic polymers that are used to form hydrogels and hydrogels can be created
from either synthetic and naturally derived materials, or a composite material
comprised of both.

1.5.2 Classification of hydrogels
Natural derived materials can be a desirable material to form hydrogels for

tissue engineered scaffolds due to their naturally occurring prevalence in the human
body. These naturally occurring polymers include agarose, alginate, collagen,

chitosan, fibrin, gelatin, and hyaluronic acid, which are used based on the fact that
they either naturally occur in the extracellular matrix or contain macromolecular
components similar to the ECM.

Collagen specifically is a very attractive material for the use in these

hydrogels, due to its abundance in mammals as the main protein occurring in the

ECM. To date, there have been 28 different types of collagen discovered, and each

type of Collagen is composed of three polypeptide chains, which wrap around each
other, binding using hydrogen and covalent bonds, to form a triple-helix structure

that is shown in Figure 15. Another reason collagen is a desirable scaffold material
is the fibers have the ability to self-aggregate into the three stranded structure and

form stable fibers. Collagen degradation is relatively easy to control through the use
of collagenase, allowing its incorporation into an engineered hydrogel fairly easily
and the degradation from the body in a locally controlled manner.
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Figure 15: Formation of the triple helix structure of collagen26

Other materials that have been investigated as possible hydrogel scaffold

materials include hyaluronic acid and chitosan, due to their structural similarities to
that of naturally occurring glycosaminoglycans (GAGs). These GAGs are found in

every living mammalian tissue and are important to the wound healing process of
diseased tissue. The degradation of these materials are also easily controlled

through the use of enzymes, hyaluronidase and lysozyme respectively. While there
are no FDA approved gels for the encapsulation and injection, currently many
natural hydrogels on the market that have proven cell-viability.

These naturally derived materials are usually used to replicate the ECM and

other cellular structures that have degraded through one of the various degradation
methods, or to otherwise to act as biological carriers for cells into the body.
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Due to the somewhat unpredictable nature of naturally derived materials,

sometimes the hydrogel should be derived from a synthetic polymer. These

synthetic polymers are much easier for scientists to reproduce with consistent
mechanical and degradation properties. The gelation properties can also be
controlled through the manipulation of the specific properties of the

Three examples of synthetic materials that are commonly used for hydrogel

applications: PEO, PVA, P(PF-co-EG). PEO is formed using a photoinitiator and a

subsequent exposure to UV radiation. These hydrogels are thermally reversibly, or
able to be de-gelled, and are also able to be combined with the co-polymers PLA.
PVA can be used in space filling and drug delivery applications, and can be

crosslinked with different chemicals or other polymer solutions to form hydrogels.
However, once it is cross-linked with other polymers it is no longer dissolvable in
aqueous solutions.

These synthetic materials are generally used in space filling and drug

delivery biomedical applications. This is due to the materials’ ability to be

controlled using crosslinking or combining with other polymers. The major

advantage of these synthetic materials is their ability to be controllably combined

with other polymers for delivery into the body or otherwise change the properties
of the formed hydrogel. However, these materials are not advantageous for cell

delivery applications due to their harsh fabrication conditions

In order to achieve the desired properties required for certain biomedical

applications, some of these hydrogel materials need to be combined. The hydrogels
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are labeled composite hydrogels and can be a mixture of synthetic and natural

derived material, synthetic with another synthetic material, or natural and another
natural material. One specific example of a composite hydrogel is the combination
of hyaluronic acid with collagen. This hydrogel is combined for the purpose of

combining the structural integrity of collagen with the wound healing properties of
GAGs.

While the material the hydrogels are derived, or the source material, from is

a very effective way of classifying and sorting the different types of hydrogels, this is
not the only way to sort them. Sometimes certain properties may be desired in a

hydrogel, meaning that it is very useful to sort the hydrogels based on their other
properties. These classifications can include the polymeric composition,

configuration, type of cross-linking, physical appearance, or network electrical
charge.27

1.5.3 General properties of hydrogels
When designing a hydrogel, there are specific design variables of the

hydrogel that need to be of concern. These design variables are contingent on the
type of application they are being applied to and the environment they are being
deployed in. The general properties of the ideal hydrogels are, as defined by
Ahmed: 27

1) Highest absorption capacity in saline

2) the desired rate of absorption for the application
3) Highest absorbency under load
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4) The lowest soluble content (resilience in application) and lowest residual
material post-gelation

5) Neutral pH of end product (post formation of hydrogel)
6) Photo-stability (resistant to chemical change)

7) Degradation without toxicity to surrounding environment
8) Durable in a saline or swelling environment and stable
9) Total non-toxic, odorless, and colorless

10)Re-wetting capability, or the ability to return the original solution if
required

11)The lowest cost material possible

It is impossible to find a hydrogel that incorporates excellence in all of the

characteristics described above, as some of the characteristics are contradictory to
each other. This means that some sacrifices must be made in order to obtain the
ideal hydrogel for specific applications. In order to choose the best possible

hydrogel, one must take into consideration the importance of each characteristic to
their specific application and then optimize the balance between contradictory
properties.

1.5.3.1 Environmental stimuli sensitivity of hydrogels
Hydrogels precursors are typically made up of a polymer network that has

been highly hydrate into a solution of the polymer. In order to have these soluble
polymers form a solid structure, they must be cross-linked in one of a variety of

different methods. The properties of a hydrogel rely heavily on the type of cross36

linking method. Using a physical stimuli response will yield a reversible bond in the
polymer chains, yielding a very weak hydrogel composed of hydrogen bonds.28 As
shown in Figure 16, the other type of cross-linking method is a chemical stimuli,

which always results in a strong hydrogel via covalent bonds. Using these different

types of cross-linking methods, different properties of the hydrogel can be achieved.
As previously stated, if a strong hydrogel is desired then a chemical cross linking
method, such as pH or use of specific solvents. These hydrogels may be stronger
than those the physical cross-linking method, but the chemical cross-linking can

affect biocompatibility and biodegradability. Thus, sometimes it is desirable to use a
physical stimuli, which requires no potentially toxic method to cross-link the

hydrogel. This means it is probably desirable for cell encapsulation than that of the
chemically cross-linked hydrogels. The softer hydrogels (formed by physical

stimuli) also can minimize the irritation to the surrounding tissue caused by their
introduction to a site of injured tissue. Ultimately, it is possible to change the

chemical and physical properties of a hydrogel scaffold by manipulating the method
of cross-linking of the polymer network.

These environmental stimuli don’t only affect the way that hydrogels initially

cross-link and form. The various stimuli can affect the properties of the swollen

hydrogel as well. A thermosetting hydrogel, when in a heated environment, can also
be swollen to a greater extent by submerging it in the desired fluid to be imbibed in
the hydrogel.29 This is especially important when proposing to inject a

thermosetting hydrogel into physiological conditions, because this means the
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hydrogel, if it has not reached equilibrium prior to injection, will uptake some bodily

fluid and this will change the porosity of the hydrogel.30

Figure 16: Various stimulation methods to initiate the swelling of the hydrogel27

1.5.3.2 Porosity and microarchitecture

The porosity of a tissue engineered scaffold is very important for tissue

regeneration. Due to their swollen structure hydrogels have the advantageous
characteristic of having an increase in the porosity of their structure, while

maintaining the structural components of the extracellular matrix.31 This increased

porosity is beneficial to the biological performance of the tissue because it allows for
a beneficial impact on their diffusion of nutrients and oxygen. This allows for a

superior environment to the traditional tissue engineered scaffold, because this
environment will allow for local angiogenesis to occur, which is required for

vascularization.30 The porosity of these hydrogels are also controllable through the

swelling or cross-linking of the hydrogel, as well as the addition of electrospun
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fibers or freeze-drying the scaffold. This is very important because different

porosities are useful for different applications in specific tissue regeneration. The
optimal pore sizes for neovascularization and fibroblast growth is 5-15μm, adult

skin tissue is 20-125μm, 100-350μm for bone regeneration, and 500μm for rapid

vascularization.30 Thus, the larger pores of hydrogels can be used for different

applications in biomedical engineering for designing scaffolds. The voids caused by

the large pores can be filled with medication that can be used for drug delivery. Due
to the hydrogels degradation, usually by hydrolysis, a drug can be controllably

delivered over time using the encapsulation of the drug in the hydrogel.27 This

porosity property is also useful for cell-encapsulation.

1.5.4 Importance of rheological properties for cell encapsulation
When trying to inject a cell seeded solution through a small diameter needle,

the shear stresses can have a large effect on the viability of the cells. This is due to
the cells lack of protection to the shear stresses, which can induce apoptosis in

cells.32 The use of a hydrogel in cell encapsulation becomes much more important

when injecting, because of the hydrogel’s ability to protect the cells from the shear

stress, due to their high viscosity.33 Most naturally occurring hydrogels also exhibit

a rheological characteristic known as stress-thinning. This property is important to
the injection method because the viscosity of the hydrogel decreases as it is

subjected to the shear stress from the wall of the needle, leading to the lubrication of
the needle from the less viscous form of the hydrogel, allowing the rest of the

hydrogel to flow through the needle with less resistance. This further protects the
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cells encapsulate from the stresses of the needle, allowing for a high viability of
injection.34

1.5.5 Mechanotransduction and cellular interactions with hydrogels
Most hydrogels can be formed at mild, physiological condition when

compared to traditional scaffolds developed in tissue engineering. For this reason,
hydrogels are regarded as a very promising material for encapsulating cells in the

regenerative medicine community. Some specific characteristics of hydrogels that
are particularly crucial to cell survival on a scaffold are the following:
1. Ability to be remodeled by cells35

2. Permeability to nutrients, oxygen, and metabolic waste36
3. Ability to mimic the ECM structure of natural tissue35

4. Viscoelastic tissue properties37

One of the most important characteristics of the cell-hydrogel interaction is

the ability of the cell to take the hydrogel scaffold and restructure it into a tissue-like
structure. This behavior is imperative to the tissue growth and the repair of

damaged tissue. The mechanical interactions with the hydrogel result in the

embedding of the cells into the hydrogel is the mechanism by which these cells

remodel, as can be seen in Figure 17.35 For this reason, hydrogels have been used as
3-dimensional constructs for the study of how the cell interacts with remodeling,
repair, and regeneration of damaged tissue, based on the biochemical and
mechanical stimulation of the environment surrounding the cells.
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Figure 17: Cellular interaction with the hydrogel35

The ability of these scaffolds to be viable and remodel makes them

potentially ideal scaffolds.38 The ability for the cells to remodel the hydrogel

scaffold lies within the cell surface receptors called integrins.35 These integrins

allow the cells to bind to ligands inside the hydrogel, those on the collagen strands,
and initiate remodeling. These ligands are available on collagen and fibrin, though
not on other hydrogels such as those made from agarose and alginate. The

morphology of those cells that have attached is different than those that have not

initiated attachment. In cells that have adhered to the ligands of the hydrogel, there
is a distinct spread morphology. Those cells that have been encapsulated in

hydrogels without available binding sites cannot adhere, and therefore do not
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exhibit this spread morphology. Instead, they appear rounded and lack visual fiber
attachment throughout.39

The cellular adhesion throughout the scaffold is not the only type of

stimulation that leads to proper cell activity for cellular regeneration.

Mechanotransduction, or the effect of mechanical forces on cellular behavior, has

proven to be very important in the correct cell activity.40 The application of these

forces change the cytoskeleton structure, leading to activation of ion channels and
phosphorylation. The opening of the correct ion channels leads to the signaling

molecules being released, signaling correct pathways. These forces can be replicated
in vitro using a bioreactor, using a different type of bioreactor based on the types of
forces desired to be replicated.41

1.5.6 Applications for hydrogels in tissue engineering
1.5.6.1 Hydrogels used for drug delivery and cell encapsulation
The cell delivery therapy considers the importance of the presence of

healthy, living cells at the target site but it does not solve the problem of cellular

retention. Injectable hydrogels were proposed to be the solution to this problem,
allowing for the cells to bind to the hydrogel.42 Some of these hydrogels are

naturally derived from a decellularized version of the tissue that the hydrogel is

being applied to, such as decellularized myocardium used as a scaffold for ischemic
myocardium therapy. Other hydrogels are made from synthetic materials, such as

Poly-acrylic acid hydrogels, and composite hydrogels that are a combination of two
different types of materials.
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The synthetic hydrogels give the distinct advantage of control of the

components in order to control and optimize the properties of the gel. These gels

can be manipulated to have stronger mechanical properties than naturally derived

gels and therefore have been a strong interest in cardiovascular tissue engineering.
While these gels show promise in multiple applications, such as drug delivery and
mimicking the extracellular matrix, a large majority of these materials have

drawbacks in their biodegradability or stimulation of the inflammatory response.
When using a material for cell delivery, the FDA requires at least 70%

viability upon completion of the study.32 If this viability is not achieved, other
cytotoxicity testing is required to test for potentials cytotoxins in the material
causing cell death.

Figure 18: Strategy for encapsulating cells inside a hydrogel scaffold43
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1.5.6.2 Hydrogels used for tissue replacement or regeneration
In designing a hydrogel that can serve as a tissue replacement or to

regenerate damaged tissue, there are a few design variables that are advantageous
for those applications. The following characteristics of a hydrogel are particularly

advantageous in the use of artificial muscles: the hydrogels must be biocompatible,
have material properties similar to the tissue that they are simulating, non-

biodegradable, able to have its properties manipulated chemically, have an easily
adjusted shape, and be a low-cost to manufacture. Furthermore, these gels must
have the ability to expand and contract under the pressures that the native
biological tissue is subject to in physiological conditions.
1.5.7 Cardiac repair via injectable hydrogels

There has been a shift in recent research to the use of non-invasive

treatments to facilitate the repair of damaged cardiac tissue. This shift has led to

much research in the field of hydrogels. The need for these hydrogels arose from
the lack of effective treatments, with the inability to treat ischemic cardiac tissue

post myocardial infarction a large motivating factor. The damaged tissue has been
treated via a combination of pharmaceutical agents, interventional therapies via

medical devices, or heart transplantation. Heart transplantation was the only truly

effective of these techniques in the treatment of these diseases, while the other two
only work to optimize the function of the remaining living tissue.44 Due to heart

donors being in very short supply, the need for an alternative treatment method is
very apparent.
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This alternative treatment needs to allow for growth and repair of the tissue

without the need to remove or replace the damaged tissue. One of the proposed

treatment methods to solve this need is cell delivery via injection of the appropriate
cell type or stem cells at the site of the damage, thereby providing the proper

cellular components to the ischemic tissue. Unfortunately, this procedure has a low
yield of cell retention at the target site and therefore is not a highly effective

procedure. However, this idea gave rise to the idea of cellular therapy via a different
delivery method such as delivery via drugs or delivery via cell-encapsulated

hydrogels.
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CHAPTER 2: PROJECT AIMS
AND RATIONALE
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The valve replacements that are currently on the market have many draw backs to
their use, including the lifelong need for anticoagulants, or the wearing down of the
replacement. There is also usually an invasive surgery that is required, which results in
There are currently many endeavors to create the ideal heart valve replacement through
the use of tissue engineered constructs, using various methods. However, there is a
growing need for a non-invasive treatment method, designed for the high risk patients
that are not strong candidates for a valve replacements. The motivation behind my
project is to create a new material that will be injected non-invasively, in order to act as a
delivery method for stem cells to the diseased or damaged site on an aortic valve.
The specific aims of my project to contribute to the landscape of tissue
engineering efforts to create an effective and long-lasting treatment for heart valve
disease include:
1. To fabricate and optimize a novel hydrogel scaffold derived from

decellularized porcine aortic cusp tissue for aortic valve applications

2. To achieve and optimize the encapsulation of the hydrogel scaffold
through seeding of hADSCs

3. Create a method to transition hydrogel into the bioreactor for dynamic
conditioning
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CHAPTER 3: MATERIALS AND METHODS
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3.1 Study 1: Fabrication of hydrogel using decellularized aortic cusps
3.1.1 Collection and harvesting of porcine aortic cusps
Porcine hearts were received from Snow Creek Meat Processing immediately

after death and put on ice. The hearts were then put in a bucket of ddH2O on ice

while setting up the tools for harvesting. The aortic root was isolated from the rest

of the heart and the rest of the heart was disposed of in biohazard waste. The major
vessels, atria, fat and ventricular muscle were removed from the heart so that only

the aortic root and mitral flap (5-10 mm past the base of the cusp) remained. Figure
19 shows the appropriate size of the harvested aortic root, keeping the aortic root
and cusps intact with no damage to the desired tissue.

Figure 19: Harvested aortic root for decellularization.
(Left) Side view of the aortic root showing the mitral flap and
aortic root. (Right) Top View, inside of aortic root and aortic
cusps
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3.1.2 Decellularization of porcine aortic cusps by immersion
Each root was decellularized in detergents already shown to be effective in

decellularizing cusp tissue, while maintaining its extracellular matrix structure. The
tissue was briefly washed in changes of distilled water and stirred in 0.02% sodium
azide overnight. The tissue was then rinsed in ethanol and water, stirred again in

0.02% sodium azide overnight, and rinsed in phosphate buffered saline (PBS) for

one day. The aortic roots are immersed in a DNase/RNase solution at 37 oC for two
days, and then rinsed with PBS for one day. The aortic roots were sterilized using
0.1% Peracetic acid and rinsed PBS for one day, then the cusps were dissected to

remove the remained of unwanted tissue so only cusps remain, shown in Figure 20.

Figure 20: Aortic Cusp Harvesting

50

One cusp was removed, processed, sectioned at 5 µm and stained with

hematoxylin and eosin (H&E) to confirm the absence of cells. Fresh aortic cusps
were also processed, sectioned at 5 µm and stained for H&E as a reference.

Following the decellularization process, the aortic cusps were deconstructed and
lyophilized using the following procedure to create a powder.

3.1.3 Decellularization verification of aortic valve tissue
Sufficient decellularization was first verified with agarose gel electrophoresis

and histology using hematoxylin and eosin, DAPI fluorescent, and Movat’s
Pentachrome stains. Fresh and decellularized samples were fixed in 4%

paraformaldehyde overnight (24 hours maximum) placed in a processing cassette,

paraffin-embedded using the automatic tissue processor according to the following
preset protocol.
•

10% buffered formalin (1 min) at 37oC

•

10% buffered formalin (1 min) at 37oC

•

70% ethanol (15 min) at 37oC

•

80% ethanol (15 min) at 37oC

•

95% ethanol (15 min) at 37oC

•

95% ethanol (15 min) at 37oC

•

100% ethanol (15 min) at 37oC

•

100% ethanol (15 min) at 37oC

•

Xylene (5 min) at 37oC
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•

Xylene (10 min) at 37oC

•

Paraffin (15 min) at 60oC

•

Paraffin (15 min) at 60oC

•

Paraffin (15 min) at 60oC

•

Paraffin (15 min) at 60oC
Samples were then stored in a warming drawer and the tissue samples were

embedded in blocks of hot paraffin on the back of the cassettes, cooled using a cold
plate at -5°C and then transferred into a bucket of ice water for sectioning. The
embedded samples were then sectioned at 10 µm using a microtome and the

sectioned paraffin ribbons were transferred to a water bath at 44°C and carefully

mounted on glass microscope slides by moving the slides underneath the ribbons

without disturbing air bubbles that build up on the bottom of the water bath. The
slides were then patted dry using a kimwipe, then put in a plastic slide holder and

transferred into an oven at 60°C to bake the tissue sample onto the slide. The slides
were then deparaffinized in xylene for 5 minutes, rehydrated in a succession of

dilutions of ethanol and are now prepared for various stains, including: hematoxylin
and eosin (H&E), DAPI fluorescent, Movat’s pentachrome, and Masson’s trichrome.
3.1.3.1 Histology: Hematoxylin & eosin staining and imaging

The following protocol for H&E staining was established and verified by the

Clemson University Bioengineering Department. After the rehydration series from

above, the slides are rehydrated in ddH2O, stained in hematoxylin for 7 minutes,

rinsed with ddH2O and tap water, and stained for eosin for 45 seconds. The samples
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are then dehydrated in a series of concentrations of ethanol and xylene.

Immediately put coverslips on the microscope slides using paramount medium to
glue the coverslips on allow to dry. The samples were then imaged using a light
microscope at 10X, 20X, and 40X magnifications.

3.1.3.2 Histology: DAPI nuclear staining and imaging
After the rehydration step, the slides are rinsed in ddH2O and mounted using

Vectashield mounting slips with DAPI fluorescent medium. The slides are place in a
closed slide holder in order to keep slides in the dark, and placed in refrigerator

(4°C) and allowed to dry. The slides are then imaged in the dark using a fluorescent
bulb on a light microscope and a blue fluorescent filter.

3.1.3.3 Histology: Masson’s Trichrome and imaging
After the rehydration step, slides are rinsed in ddH2O and fixed using

Boulin’s fixative at 56°C for one hour. Samples were rinsed with running tap water
for 10 minutes and then stained with Weigert’s iron hematoxylin working solution

for 10 minutes. Samples were again rinsed with warming tap water for 10 minutes,
washed in ddH2O and stained with Biebrich scarlet-acis fuchsin solution for 10-15
minutes. After the Biebrich staining, the samples were washed in ddH2O and

differentiated in phosphomolydic-phosphotungstic acid solution for 10-15 minutes.
Without rinsing, sections were transferred to aniline blue solution for 5-10 minutes
and then rinsed with 1% acetic acid solution for 2-5 minutes. Distilled water was
then used to wash the samples, dehydrated in ethanols, and cleared in xylene.
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Coverslips were then mounted using paramount medium and the samples were
then imaged using a light microscope at 10X, 20X, and 40X magnifications.
3.1.3.4 Histology: Movat’s Pentachrome and imaging

After the rehydration step, slides are rinsed in ddH2O and placed in 1%

Alcian Blue for 20 minutes. The samples are then washed using running tap water
for 3 minutes and place in alkaline alcohol (pH=8) for 2 hours. The samples are

washed again with running tap water for 10 minutes, then rinsed in 70% alcohol,
placed in Resorcin Fuchsin Working Solution for 16 hours. The samples were
washed in running tap water for 10 minutes, rinsed in ddH2O, and placed in

Weirget’s Hematoxylin Working Solution for 15 minutes. Tap water and ddH2O

were used to rinse again and the nuclei are then differentiated using Woodstain

Scarlet—Acid Fuchsin Solution for 5 minutes, rinsed using 0.5% Acetic Acid, and

differentiated in 5% Phosphotungstic Acid for 10-20 minutes. Again, the samples

were rinsed in 0.5% Acetic Acid and rinsed thoroughly with 100% EtOH. Saffron Du

Gratinais was used for 15 minutes and then the samples were dehydrated in a series
of dilutions of ethanol and xylene and coverslips were immediately mounted using
paramount mounting medium. The samples were then imaged using a light
microscope at 10X, 20X, and 40X magnifications.

3.1.3.5 Agarose gel electrophoresis for DNA loss verification
Both native and decellularized aortic cusps had their DNA purified using the

Qiagen Kit, following the manufacturer’s instructions for tissue samples. The

agarose gel was formed by placing 1% agarose gel in the microwave for 1.5 minutes,
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cooled to 60°C and 10μl of ethidium bromide is added to the gel. The gel is then

poured in the mold and the comb is placed based on the number of combs. The
standard and samples were loaded into each well and were run at 100V for 60

minutes. The gel was imaged using the ethidium bromide setting on the ChemiDoc
MP+ BioRad imaging system.

3.1.4 Powdered aortic cusp preparation
In order to prepare a sterile powdered aortic cusp tissue, each cusp was first

shredded into small pieces using sterile scalpel blades. The tissue was then blended
using the homogenizer at the maximum speed setting. The tissue was lyophilized
and weighed in preparation for the next step, stored in freezer (-20oC) if not

immediately preparing solubilized tissue solution.

3.1.5 Preparation of solubilized aortic cusp for gelation
To generate a gelation form of cusp extracellular matrix, the decellularized

matrix was solubilized using a method adopted from a previously published
protocol by K.L. Christman.42 Pepsin (Sigma P7125, 400 U/mg) and 0.01 M
hydrochloric acid (HCl) solutions were first used to determine the optimal

concentration of pepsin to digest the ground tissue matrix. The ideal pepsin:matrix

ratio was found to be 1.5:1 (m/v), or 600 units of Pepsin per milligram of aortic cusp
tissue, and a 10:1 concentration of 0.01M HCl:matrix (m/v) was used. The matrix
was allowed to digest for 48 hours under constant shaking, via an orbital shaker,

until completely solubilized. The solution was then neutralized to a pH of 7.2-7.6 by
the addition of sodium hydroxide (0.1N NaOH) and diluted using a 1:10
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concentration of chilled 10X PBS and 1X PBS to dilute to the desired concentration
of 6 mg/ml. The final solubilized matrix was then incubated at 37oC for two hours

to induce gelation process. In order to inhibit the gelation of the solutions, keep on

ice for short term storage store at 4°C until use, for long term storage store in -80°C.
3.1.6 Preparation of PureCol® hydrogel

The protocol for preparation was adapted from the Advanced BioMatrix

manual for PureCol®, Bovine Collagen Solution, Type I (3 mg/ml). While keeping all
solutions on ice, add 1 part 10x PBS to 8 parts collagen solution. The pH was

adjusted using 0.1 M NaOH to 7.2-7.6, monitored using a pH paper strip. The final

volume was brought to 10 total parts with sterile 1xPBS. To initiate gelation, the gel
was warmed in incubator (37°C) for approximately 1 hour.

3.2 Study 2: Characterization of aortic cusp-derived hydrogel

3.2.1 Thermal gelation of hydrogel
The thermal gelation was evaluated using a temperature controlled water

bath, increasing the temperature every 5 minutes from room temperature (25°C)
until the gelation point is reached. Gelation was tested using the inversion test,

where the solutions were inverted inside a micro-centrifuge tube at each time point,
until the solution was no longer fluid inside the tube. The time of the complete loss
of fluidity, or full gelation, was recorded for each gel solution.
3.2.2 Swelling and solubility behavior of the hydrogel

In order to quantify the swelling behavior and equilibrium water content, a

swelling behavior assay was performed, adapted from Sanders, 2014.45 Solutions of
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the hydrogel immaterial were prepared at as described above at a volume of 100 µl
samples and at three different concentrations of gel; 6mg/ml, 4.5mg/ml and

3mg/ml of the aortic cusp derived gel and a PureCol® gel. The hydrogels were

allowed to form for 24 hours at 37°C, and weighed yielding the initial wet weight

(Ww1) of each hydrogel. Each of these hydrogels were frozen at -80°C, lyophilized

for 24 hours and weighed (Wd1). The hydrogels were then allowed to swell in an

excess amount of 1X PBS (pH=7.4) at 37°C for 24 hours. The excess buffer on the
hydrogels were then blotted off and the hydrogels were weighed (Ww2). The

hydrogels were again frozen at -80°C, lyophilized for 24h and weighed (Wd2).

Where ρ𝑔𝑔 is the hydrogel density and ρ𝑠𝑠 is the density of 1X PBS (1 g/ml).

The equilibrium water content (%EWC) is calculated using the following equation:
%𝐸𝐸𝐸𝐸𝐸𝐸 =

(𝑊𝑊𝑤𝑤2 − 𝑊𝑊𝑑𝑑2 )
𝑥𝑥100
𝑊𝑊𝑤𝑤2

Equation 1: Equilibrium Water Content Percentage of Hydrogel45

Equation 2: Calculation of the solubility of a hydrogel

3.2.3 Collagen content quantification of hydrogels
The samples were frozen (-80°C) overnight and lyophilized to obtain 10-

15mg of dry weight. The samples are submerged in 4N NaOH and hydrolyzed at
120°C for two hours. Complete the hydrolysis inside a hydrolysis bottle and

covered in tin foil in order to avoid evaporation of the sample. Using 1.4N citric
acid, the solution should be neutralized to a pH between 7.2 and 7.6. The final
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volume of the sample is measured and allow the precipitate to fall off before

analyzing the solution. Add the 200-μl of the sample into a small borosilicate tube,

adding one mL of Chloramine T to each sample and the standard, allow to incubate
at room temperature for 20 minutes. Add 1-mL of the PDMAB solution (p-dimetilamino-benzaldehyde, n-propanol, 60% H2SO4) to the samples and standards to

create the colorimetric binding of the sample. The samples should be vortexed and
incubated at 65°C for 15 minutes, again covering with tin foil to avoid evaporation.

The samples are each then pipetted in triplicate and the standards in duplicate into
a 96-well plate are pipetted at a volume of 300-μl. The plate is read using a plate

reader and the Gen5 software, at an optical density of 550nm. A standard curve is
made using the standard readings, and a trend line is created to obtain the

concentration of hydroxyproline that corresponds to the absorbance reading. The
collagen percentage in the tissue is then calculated based on the equation below.
% 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑖𝑖𝑖𝑖 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 =

100 ×

𝜇𝜇𝜇𝜇 𝐻𝐻𝐻𝐻𝐻𝐻
× 𝑉𝑉𝑉𝑉𝑉𝑉 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 × 8.33
𝑚𝑚𝑚𝑚
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤ℎ𝑡𝑡 (𝑚𝑚𝑔𝑔)

Equation 3: Calculating the percent collagen in a construct from a hydroxyproline assay

3.2.4 Rheological studies for viscosity of hydrogel
The viscosity of the aortic cusp-derived hydrogel precursor was tested using

the Brookfield DVIII Ultra Programmable Rheometer. One-mL of hydrogel

precursor was injected onto the CP42 spindle and run using the parameters in
Figure 21, each ramp being run for 3 minutes, for a total of 15 minutes per

experiment. The viscosity of the precursor solution was then first calculated using
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Equation 4, where F/A=shear stress, η is viscosity and V/h=shear rate. Therefore,

the apparent viscosity can be found as the slope of shear stress vs. shear rate. The
fluid was then fit to a better model, the Power Law model, which is used for fluids

that exhibit a non-Newtonian behavior. The viscosity was then compared to
literature values of PureCol®.

Ramp 1
Ramp 2
Ramp 3
Ramp 4
Ramp 5

Experiment
1

Experiment
2

Experiment
3

1 RPM

1.00 RPM

1.00 RPM

4 RPM

7.75 RPM

11.50 RPM

2 RPM

3.25 RPM

3 RPM

5.50 RPM

5 RPM

10.0 RPM

Figure 21: Protocol used for Rheology

𝑉𝑉
𝐹𝐹
= 𝜂𝜂 ∗
ℎ
𝐴𝐴

4.50 RPM
8.00 RPM

15.00 RPM

Equation 4: Equation for viscosity of a Newtonian fluid46

𝜂𝜂 = 𝑘𝑘𝛾𝛾 𝑛𝑛−1

Equation 5: Power law model for pseudoplastic materials33

3.2.5 Porosity analysis of aortic cusp hydrogel, decellularized cusp, and
PureCol®
The H&E sections were analyzed using the ImageJ software for porosity size,

number of pores, and overall area of the pores. In order to do this, the scale was set
using the scale bar in the image, the threshold was set so the pores appear red

(Figure 22: Porosity protocol for H&E sections (Figure 22, left). The feret’s diameter

(Figure 22, right) was then analyzed of each pore using the software. The results
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were transferred into an excel file and averaged across three photos (n=3) for each

study group. A student’s t-test was used to analyze the difference in pore size, pore
number and overall area of the pores across all samples.

Figure 22: Porosity protocol for H&E sections

3.3 Study 3: Encapsulation of hADSCs onto different hydrogel scaffolds
3.3.1 hADSCs culture and subculture
Human adipose stem cells were removed from cryopreservation liquid

nitrogen and rapidly warmed using a water bath at 37°C. The cells were transferred
into approximately 5-mL of fresh, warmed culture media (90% 1x DMEM, 9% Fetal
Bovine Serum, 1% Antibiotic/Antimycotic) and centrifuged at 12,000 rpm in order

to achieve a cell pellet. The culture media was aspirated, the cells were resuspended
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in fresh, warm culture media and were plated onto a Corning T-175 flask at a

density of about 5,000 cells/cm2. Culture media was replaced every 3-4 days.

In order to subculture the cells, cell were rinsed with warmed PBS, aspirated,

then trypsin EDTA was used to detach the cells from the flask for 5-7 minutes. The

trypsin was deactivated using culture media and the cell suspension was

transferred to a 50 mL conical tube. The cell suspension was centrifuge at 12,000

rpm for 5 minutes to achieve a pellet, the old media was aspirated off, and the cells

were resuspended the cells in fresh culture media. The cells were then re-plated on

T-175 flasks at the desired density.

3.3.2 Encapsulation of hADSCs onto hydrogel scaffolds
All steps for this study were performed in sterile conditions. The aortic cusp

hydrogel and PureCol® precursor solutions were made as described previously

(3.1.5) up until the addition of 1X PBS, which was replaced with DMEM culture

media for this study. The hydrogel precursor was kept on ice until cells were ready
to encapsulate. The cell culture of hADSCs was passaged as described previously

(3.3.1) and the cells were counted using the cell scepter in order to determine the
total number of cells. The cells in culture media were then transferred into the

hydrogel precursor solutions in order to achieve a cell density of 800,000 cells/mL

in both of the solutions. The precursor solutions were then brought to their desired
concentration using DMEM culture media (6 mg/ml for the aortic cusp derived

hydrogel and 3 mg/ml for the PureCol® hydrogel). The solutions are mixed via

pipette mixing, note that the aortic cusp derived hydrogel is extremely viscous and
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the pipette tip needed to be cut wider using a sterile razor blade in order to

successfully pipette. The hydrogel precursors were plated on a 24-well place at a

volume 0.5-mL per well using the schematic shown in Figure 23.

Figure 23 : Schematic for cell encapsulation in hydrogels plating on a 24-well plate.

Once hydrogels were plated, the well plate was placed in incubator (37°C, 5%

CO2) for two hours to ensure full gelation. After full gelation has occurred, 1-mL of

DMEM culture media was pipetted on top of the hydrogels without disturbing them.
The culture media was changed every 3 or 4 days, being careful not to disturb the

hydrogel on the plate. Images were taking every 24 hours using the ChemiDoc MP+
BioRad system for contraction analysis. This study was run for a total of 24 days.
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3.3.3 Contraction analysis of hydrogels
The images taking daily from the ChemiDoc MP+ BioRad system, the images

were imported into the ImageJ software. Using the drawing tool in ImageJ, each

hydrogel was outlined every day and the surface area was taken using the measure
function. The scale was based on the known dimensions of a 24-well plate. The

surface areas of each test group was averaged and graphed as a function of time.
3.3.4 LIVE/DEAD cytotoxicity assay

The media from each well was aspirated in the plate as washed using pre-

warmed 1XPBS. The Live/Dead assay from Molecular Probes was used to evaluate
the viability of the cells on each hydrogel after 24 days. A mixture of 4mM Calcein
AM, 2mM ethidium homodimer-1 (EthD-1) in 1XPBS was used to stain the wells.
The well plate was incubated for 20 minutes at 37°C, and then imaged using a

fluorescent microscope using a green filter for living cells and red filter for dying or
dead cells.

3.4 Study 4: Hydrogel encapsulation of hADSCs in varying concentrations

3.4.1 Encapsulation of various concentrations of hADSCs in aortic cusp
hydrogel
All steps for this study were performed in sterile conditions. The aortic cusp

hydrogel precursor solution was made at a concentration of 6 mg/mL, as described
previously (3.1.5) up until the addition of 1X PBS, which was replaced with DMEM
culture media for this study. The hydrogel precursor was kept on ice until cells

were ready to encapsulate. The cell culture of hADSCs was passaged as described
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previously (3.3.1) and the cells were counted using the cell scepter in order to

determine the total number of cells. Prior to seeding of the cells, 100μL of hydrogel
precursor was coated onto each well in order to ensure that no cells would adhere to
the well plate and would stay on inside the scaffold until full gelation took place. The
hydrogel precursors were then seeded at the densities described in Figure 24: Cell

seeding schematic for study 4 Pictures were taken every day using the ChemiDoc MP+

BioRad Imager in order to gather the images necessary to do the contractile analysis
described in the prior study (3.3.3).

After 13 days, a Live/Dead assay was run on each sample in accordance with

the protocol described earlier (3.3.4).

Figure 24: Cell seeding schematic for study 4
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3.4.2 Contraction analysis of hydrogels
The images taking daily from the Chemi Doc MP+ BioRad system, the images

were imported into the ImageJ software. Using the drawing tool in ImageJ, each

hydrogel was outlined every day and the surface area was taken using the measure
function. The scale was based on the known dimensions of a 24-well plate. The

surface areas of each test group was averaged and graphed as a function of time. A
student’s t-test was used to analyze the difference in contraction rate across all
samples at every time point.

3.4.3 Quantification of glycosaminoglycan content using DMMB assay
The samples were frozen (-80°C) overnight and lyophilized, dry weights of

each sample were recorded for normalization. Sample are digested using 1-mL of

15mg/ml proteinase K in 30mM Tris Buffer (pH 8.0) for 24 hours at 50°C. In a 96

well plate, a 1:24 mixture of the sample and Tris Buffer is transferred in each well

and was combined with 200 of DMMB reagent (40mM NaCl, 40mM Glycine, 46μm

DMMB). A standard was made using a 0.025 μg/μl CS stock solution in Tris-buffer.

The absorbance was immediately read at 525nm using a plate reader and the Gen5
software. Using the standard, the absorbance was related to glycosaminoglycan

(GaGs) content and the GaGs content was calculated for each sample and normalized
to their dry weight. A student’s t-test was used to analyze the difference in
chondroitin sulfate content across all samples.
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3.4.1 Viability analysis of LIVE/DEAD images
The protocol previously described in 3.3.4, live and dead images were

obtained of each group of seeded hydrogel. The viability of the cell encapsulated
was then calculated using the ImageJ program (NIH freeware) and the protocol

described by Labono.47 The cells were isolated from the image by first turning the
image to greyscale and then using the threshold feature to only visualize the cells.

Note, if there was overlap of cells, then the watershed feature was used to isolate the
cells further. The image was then turned into a binary image format (Figure 25) and
analyzed using the analyze particles feature, excluding <10μm2 to reduce the noise

of the signal analysis. The number of analyzed particles is the number of cells

counted. The percent viability is then calculated based on Equation 6: Viability
analysis equation. A student’s t-test was used to analyze the difference in cell
viability across all samples.

Figure 25: ImageJ isolation of cells
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#𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿
#𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿 + #𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷

%𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 = 100 ×

Equation 6: Viability analysis equation

3.4.2 Sample preparation for scanning electron microscopy
Scanning electron microscopy (SEM) was used to image and characterize the

surface morphology of the hydrogel samples. Each sample was fixed overnight at
room temperature using Karnovsky’s fixative (a mixture of 2.5% Glutaraldehyde,
2.0% Formaldehyde buffered with 0.1M Cacodylic Acid in ddH20). The samples
were washed with three changes of 1X PBS and then washed three times with

ddH2O. The sample is again fixed, this time incubating in a 0.1% Osmium Tetroxide
in ddH2O fixative for 30 minutes. The samples are again washed three times using

ddH2O. The samples were dehydrated using the succession of ethanol (electron
microscopy grade) changes, as follows:
•

•

•

•

•

•

50% EtOH

10 minutes

85% EtOH

10 minutes

70% EtOH

10 minutes

95% EtOH

100% EtOH
100% EtOH

10 minutes
15 minutes
15 minutes

Upon completion of the dehydration of the sample, the sample is critical

point dried (CPD) via incubation in excess of Hexamethyldislazane (HMDS) for 20
minutes. The HMDS is aspirated off and air dried at room temperature until fully

dry. The samples are stored in a desiccator overnight, in order to avoid rehydration
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of the sample. Mount the samples on aluminum stubs with double sided copper

tape and sputter coat the samples for 2 minutes with platinum using the Hummer
6.2 Sputter Coater, shown in Figure 27, at the Advanced Materials Research

Laboratory (Clemson University Electron Microscope Facility, Anderson, SC). Store

in a desiccator until imaging. The samples are imaged at the AMRL on the Hitachi S4800 scanning electron microscope at magnifications ranging from 2,000x to
50,000x.

Figure 26: Hitachi S-4800 Scanning Electron Microscope
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Figure 27: Basic Hummer 6.2 Sputter Coater, Anatech USA48

3.4.3 Collagen fiber diameter analysis of aortic cusp hydrogel
Using 50,000x images that were obtained from scanning electron

microscopy, then imported into the ImageJ software. Using the scale bar provided

by the image from SEM, the scale is set in ImageJ and the diameter of the individual
collagen fibers can be measured using the measure tool. Ten random fibers from
each sample group were measured and averaged together for comparison.
3.4.4 Sample preparation for transmission electron microscopy

Scanning electron microscopy (SEM) was used to image and characterize the

surface morphology of the hydrogel samples. Each sample was fixed overnight at
room temperature using Karnovsky’s fixative (a mixture of 2.5% Glutaraldehyde,
2.0% Formaldehyde buffered with 0.1M Cacodylic Acid in ddH20). The samples
were washed with three changes of 1X PBS and then washed three times with

ddH2O. The sample is again fixed, this time incubating in a 0.1% Osmium Tetroxide
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in ddH2O fixative for 30 minutes. The samples are again washed three times using
ddH2O. The samples were dehydrated using the succession of ethanol (electron
microscopy grade) changes, as follows:
•

•

•

•

•

•

50% EtOH

10 minutes

85% EtOH

10 minutes

70% EtOH

10 minutes

95% EtOH

100% EtOH
100% EtOH

10 minutes
15 minutes
15 minutes

Upon completion of the ethanol dehydration, leave the samples in 100%

EtOH overnight. The samples are then infiltrated using a 1:1 mixture of EPON resin
and 100% EtOH for 4-6 hours in the refrigerator (4°C), then embedded in 100%

EPON resin and placed in the drying oven (60-70°C) for 24 hours. The embedded

samples are then sectioned using the microtome (Figure 28) and a glass the sections

are captured for imaging using a small copper circle with a carbon mesh grid. The
samples are stored overnight in a desiccator to dry and then further fixed for cells
using 4% Uranylacetate for 30 minutes in the dark, in order to stain the nucleic
acids, proteins and free amino groups. This is follow by a staining of cellular

membranes using Reynold’s lead citrate, for one minute in the absence of CO2. The
samples were then dried for at least two hours prior to imaging, again in a

desiccator. The samples were then imaged using the Hitachi H7600 Transmission

70

Electron Microscope (Figure 29) at the Advanced Materials Research Laboratory
(Clemson University Electron Microscope Facility, Anderson, SC).

Figure 28: Microtome for Sectioning for
Transmission Electron Microscopy

Figure 29: Hitachi H7600 Transmission Electron
Microscope

3.4.5 Immunohistochemistry for analysis of vimentin, α-smooth muscle
actin, and laminin presence
The immunohistochemistry (IHC) protocol was adapted using the general

IHC protocol that was developed by a former lab member, Dr. James Chow. Samples
were sectioned onto glass slides as described in 3.1.3.1. The slides were

deparaffinized in xylene and rehydrated to water using succession of decreasing

ethanol concentrations. For antigen retrieval, the sections were circled using the

wax Vector Immedge Pen and 2N hydrochloric acid (HCl) was dropped onto each

individual section and incubated for 20 minutes. The slides were then rinsed using

a tris buffer saline (TBS) two times for 5 minutes. The slides were rinsed in 0.025%
triton for 5 minutes in order to permeabilize the sections and were again rinsed in

TBS for 5 minutes. A 1.5% normal blocking serum made from normal horse serum
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in TBS was used to block non-specific binding for 45 minutes. The normal blocking
serum was wicked from the slides and the primary antibody in TNB buffer was

added to the sections, Vimentin(Abcam, ab92547) at a concentration of 4ug/ml, α-

smooth muscle actin (Abcam, ab5694) at a concentration of 5ug/ml, and laminin at
a concentration of 40ug/ml (Abcam, ab11575) and was incubated at room

temperature for 1 hours. Following the primary antibody incubation, the antibodies
were extracted and saved, rinsed twice with TBS. The endogenous peroxidase was
blocked using a 0.3% H2O2 and 0.3% normal horse serum in TBS for 30 minutes,

rinsed with TBS for 5 minutes, and the secondary biotinylated antibody was applied,
made of 30μl normal horse serum and 10 μL anti-mouse in 2 mL TBS for 30 minutes
at room temperature. The slides were again washed using TBS two times for 5
minutes and then were incubated in the Avidin Biotin Complex for 30 minutes.

Again, the slides were rinsed with TBS and then were developed using the DAB

solution, made of 5mL H2O, 2 drops of Buffer Stock solution and 4 drops of DAB
solution from the Vector kit, and 2 drops of H2O2. Once the brown tint of the

sections was observed the slides were then quenched using ddH2O. The slides were
then imaged using a light microscope at the 10X magnification.

3.4.6 Western blot for α-smooth muscle actin and laminin
Using a protocol previously established by Dr. Jeremy Mercuri in the BTRL,

the protein of various samples was extracted using RIPA buffer for 20 minutes on
ice. The protein concentration was determined using a Bicinchoninic acid (BCA)

colorimetric assay. The samples were prepared so there were 20 μg of protein per
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well using reducing buffer and ϐ -mercaptoethanol. SDS-PAGE was run for 90

minutes at 100V prior to western blotting. The gels were transferred to PVDF

membranes and run for 60 minutes at 100 V. The membranes were then blocked in
2% Non-fat dried milk (NFDM) for 2 hours and then incubated in the primary

antibody in 2% NFDM. Then they were washed in Tris-Tween 3x and in 0.5% NFDM
2x, then in the secondary primary for 90 minutes. The membranes were then

washed in Tris-buffer, prepared in detection solution (Thermo Fischer) and imaged
using the ChemiDoc MP+ (BioRad).

3.5 Study 5: Injection of cell-seeded hydrogels into the base of the aortic
cusp

3.5.1 Method of injection
First the isolated aortic root was mounted in an aortic root mount, as shown

in Figure 30Error! Reference source not found.. Using the injection protocol

previously established by a student in our lab, Allison Kennamer49, the aortic cusps

were injected in the following manner. All materials were sterilized using either the
autoclave (121°C) or ethylene oxide. Human adipose stem cells were passaged, as
described in 3.3.1, and reconcentrated to the desired cell density of 3.2x106

cells/mL. One mL of the cell dense hydrogel solution was pre-loaded into three
1

separate syringes (one per cusp). Using a 27 GA x14 inch needle connected to an air
pump, sterile air was pumped into the base of the cusp at about 15-20 psi, which
inflated the cusp. Using the same size needle, about 0.5 mL of the pre-loaded

hydrogel solution was injected into the inflated aortic cusp. The same injection
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method was repeated for all three cusps on the same mounted aortic root. The root
was then transferred into the assembled valve bioreactor.

Figure 30: Sutured aortic mount
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3.5.2 Bioreactor assembly and conditioning
The valve bioreactor was assembled based on the instruction of Dr. Lee

Sierad, a former student in the BTRL. Once fully assembled, as shown in Figure 32:
Assembled bioreactor the bioreactor was filled to the fill line using 700-mL of

culture media. A second round of antibiotic/antiomycotic was added to the media
after 3 days of conditioning. The valves were pre-conditioned using a ramp up

scheme as shown in. The valve was slowly subjected to higher pressures each day,
reaching pulmonary pressures on day 3 and conditioned there for the next four
days, for a total of one week (Figure 31).

TIME (DAY)

PRESSURE (MMHG)

1

0/0

2

10/5

3

10/5

4

20/10

5

20/10

6

20/10

7

20/10

Figure 31: Bioreactor conditioning scheme.
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Figure 32: Assembled bioreactor
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3.5.3 Histological Analysis
The cusps were extracted and placed in 4% Paraformaldehyde overnight,

and then processed using the Tissue Tek Processor. They were then embedded,
sectioned, and stained for H&E and DAPI to determine if cells were viable in the
bioreactor, as described in 3.1.3.1.
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CHAPTER 4: RESULTS AND DISCUSSION
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4.1 Study 1: Fabrication of hydrogel using decellularized aortic cusps
4.1.1 Decellularization Analysis
Figure 33 shows the histological tests to determine that there was proper

decellularization of the aortic cusp. The H&E and DAPI stains both show that the

nuclei of the cells have been removed fully through the decellularization process.
The fresh aortic cusp H&E stain shows purple staining indicating the presence of

cells in the ECM, while the decellularized stain does not show this. A DAPI stain, an
immunofluorescent nuclear stain, shows the nuclei of cells as a bright blue

fluorescence. Again, the fresh show that there is the presence of cells, while the

decellularized cusp shows no presence of cells. Staining for Movat’s pentachrome

stains nuclei red, elastin dark purple, GAGs blue, and collagen yellow. It can be seen
that there is a presence of GAGs in the fresh cusp, but there is no presence of GAGs
in the decellularized cusp. The color of the gross, fresh cusp is shown to have a

brownish tint, while the decellularized cusp is shown to be a ghost white color. The
removal of DNA was examined using gel electrophoresis, as shown in Figure 34, and
it is seen in lanes 2-5 that DNA is present in fresh aortic cusps, but is absent in lanes

7-11 corresponding to the decellularized aortic cusps. This absence indicates the

proper removal of DNA and RNA during the decellularization process. Overall, the
histology and gel electrophoresis indicates that the aortic cusps were completely
and properly decellularized.
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Figure 33: Decellularization analysis of porcine aortic cusps

Figure 34: Agarose gel electrophoresis of fresh and decellularized porcine aortic cusps
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4.1.2 Fabrication of decellularized porcine aortic cusp based hydrogel
The goal of this pilot study was to successfully isolate and decellularized

aortic cusp tissue and then use the protocol described in 3.1.5 to solubilize the cusp
and fabricate a hydrogel structure at physiological conditions. Figure 35 shows the
successful fabrication of two different aortic cusp-derived hydrogels (ACG). The
comparison between the two fabricated hydrogel reveal two basic, yet key
properties of the hydrogel. Once cross-linked, this hydrogel is capable of

maintaining the structure of container that the hydrogel was formed (or cross-

linked) in. The hydrogel can be molded into both thick, 3-dimenional structures (A)
with the potential for a 3-dimensional scaffold and molded to form a desired

structure such as the shape of an aortic cusp (B). The hydrogel also shows the

ability of the hydrogel to maintain its crosslinked structure once removed from
physiological temperatures (37°C). This means that the gelation process is not

spontaneously reversible at room temperature, once the initial bonding has formed.

Figure 35: Successful fabrication of ECM hydrogel
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4.2 Study 2: Characterization of aortic cusp-derived hydrogel
4.2.1 Comparison of different concentrations of hydrogels
The goal of this study was optimize the concentration of the aortic cusp-

derived hydrogel through visualization of the reformed matrix, comparison of

characterized properties, as well using knowledge acquired from similar studies in
literature. The first step in determining what the best concentration is of

extracellular matrix in the hydrogel is do histology on the structure that is produced
via gelation (Figure 36). The H&E histology stains (36, top) reveals how the

structures form after gelation, showing that as the concentration present in the cells
decreases, the structure formed loses the distinct formation of the fibers. The

highest concentration of extracellular matrix used was 6 mg of extracellular matrix

per 1 ml of solution. This concentration showed distinct collagen fibers formed and
noticeable pores formed within the matrix, which is important for cell-seeding in
tissue engineered scaffolds. The lower concentrations (4.5 and 3 mg/ml) of

extracellular matrix hydrogels do not show the same distinct fiber formation, nor
have the same distinct pores. The lack of fiber formation in lower concentration

leads to the conclusion that there would be limited interactions with the matrix, as
there is not a distinct structure to adhere to. Their lack of distinct pores are most
likely due to the lack of sufficient concentration of collagen to reform proper

collagen fibers. Further analysis of the architecture using Masson’s Trichrome
confirmed the formation of denser collagen fibers in the higher concentration
hydrogel. Another interesting presence was discovered in the staining of the
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hydrogels, the pink color that is present indicates muscle fibers are reforming in this
matrix. This is interesting, and is probably the result of the isolation process of the

porcine valves. There is one cusp in the porcine valve that contains a mix of muscle
and collagen and elastin. What this shows is that the muscle fibers will also reform
as a result of this gelation process.

The collagen content for all three hydrogel concentrations, as well as the

fresh aortic cusp and decellularized aortic cusp was tested using a hydroxyproline
assay, Figure 37. This test was run to see how much of the collagen was retained
throughout the decellularization process, as well as the formulation of the

extracellular matrix hydrogel. It was found that the native cusp has an average

collagen content of 453 μg/mg and the decellularized cusp had an average of 445
μg/mg. These values were not found to be statistically significant, therefore the

decellularization process does not degrade the collagen in any significant manner.
The varying concentrations of aortic cusp hydrogel were also tested and found to

have values as follows: 6 mg/ml has a concentration of 255 μg/mg, 4.5 mg/ml has a
concentration of 317 μg/mg and 3 mg/ml has a concentration of 270 μg/mg. These
were not found to be statistically significant across the three concentrations, but

they were found to be statistically different from the fresh and decellularized cusp.
This difference can be explained through the process of solubilization of the ECM.

This process uses pepsin to break down and solubilize the tissue, which works by

breaking down the triple helix structure of collagen and can then become soluble.
Upon reformation, some of the collagen may not reform the triple helix structure,
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resulting in the approximately 40% loss of total collagen content by weight. This
also leads to the assumption that some other ECM components are preserved

throughout the process of fabrication of the hydrogel, due to the dry tissue weight
remaining is still around 700 μg/mg.

A summary of various other parameters of the hydrogels is shown in Figure

38, which summarizes the conditions at which these hydrogels are fabricated, the

equilibrium water content percentage (%EWC), the swelling ratio, and the solubility
percentage (%), as well as the collagen content. These parameters were all tested
against PureCol®, a hydrogel made of pure collagen already on the market. The

EWC of all the hydrogels was found to range from 97.5-99.1% indicating the high
fluid content of these hydrogel scaffolds. The swelling ratio, which indicates the

amount of fluid, relative to their own size, that a hydrogel can take in after the initial
gelation process occurs. These values ranged from15-20% with no significant

difference across all samples, meaning that these hydrogels can take in an extra

15% of fluid while in the body. This parameter is important to take in to account,
because the hydrogel should be swollen prior to injection to avoid uptake of

undesirable fluids in the hydrogel upon injection into the body. The collagen

content was also compared to PureCol®, which as its name suggests, is almost pure
collagen. Advanced Biomatrix lists its collagen content as >99% collagen type I.

While this leads to a reduction in variability in how the hydrogel performs, it means
that there is no other ECM components present in the hydrogel for proper cell

signaling and adhesion. From these studies, it was determined that a concentration
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of 6 mg/ml for the hydrogels is best for cell encapsulation, due to its similarity in
microstructure to that of the native ECM.

Figure 36: Comparison of hydrogel concentrations using histology

Figure 37: Hydroxyproline assay for collagen content
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Sample

ACG (6mg/ml)

ACG (4.5mg/ml)

ACG (3mg/ml)

Pure Col

Gelation pH

7.2-7.6

7.2-7.6

7.2-7.6

7.2-7.6

Gelation Temp(°C)

32

32

32

37

%EWC

97.5%±0.9

99.1%±0.2

97.9%±1.1

98.7%±0.3

Solubility (%)

68.3%±6.8

71.6%±21.0

77.4%±3.3

88.0%±14.5

Swelling Ratio (%)

15.3%±1.8

N/A

19.1%±3.2

10.8%±1.4

Dry Weight
Collagen Content
(μg/mg)

255 ±17.4*

316±70.1*

270±40.8*

933±48.3

Figure 38: Summary of properties of different hydrogels. (* denotes P<0.05 compared PureCol®)

4.2.2 Analysis of porosity
The porosity of a tissue engineered scaffold is a very important characteristic

to account for in tissue regeneration. The porosity of this hydrogel was quantified
using H&E sections and the ImageJ software (Figure 39), then compared to that of
the decellularized aortic cusp and the PureCol hydrogel. The pore number, pore
size, and pore area were all studied for each sample type and compared to for

statistical significance. The aortic cusp derived hydrogel was found to have much
larger pore size (47μm2) when compared to the decellularized cusp and the

PureCol®. The pore number of the AC hydrogel was decreased over the same area.
This increase in pore size seems to be inversely correlated to the pore number,

which can be explained by the pore size increasing, leading to a decrease in the area
available for other pores on the image. The pore size and pore number values were
both statistically different from the PureCol® and decellularized cusp.
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This larger pore size is conducive to the effectiveness scaffold for cell

encapsulation and migration. Thus, the fabrication of this highly porous scaffold

with cells already encapsulated in the hydrogel should help with cell migration in

the scaffold, as compared with the decellularized cusp and PureCol®. This hydrogel
also offers the advantage over a traditional tissue construct, as it is easy to

encapsulate prior to reforming the ECM, thus a uniform distribution of cells should
theoretically be attained during cell encapsulation.

Figure 39: Porosity analysis
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4.2.3 Rheological studies for viscosity of hydrogel
Three rheological trials were run using different settings for the maximum RPM
tested, plotting the shear stress vs shear rate and each fit with a power law model
(Figure 40,A). The maximum viscosity recorded was found to be 76.80 mPa*s at a

shear rate of 3.80 s-1 and the minimum viscosity recorded was 30.72 mPa*s at a shear
rate of 57 s-1 (Figure 40, B). The decreasing viscosity of the fluid was plotted against the
shear rate with a power law model trend line (Figure 40, C). These numbers were then
compared to the literature value for PureCol®, which was between 23 and 27mPa*s.50

Figure 40: Rheological analysis of hydrogel
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The rheological studies for viscosity of the aortic cusp derived hydrogel

revealed a key property of the precursor. The precursor to the hydrogel does not

behave like a Newtonian fluid, which exhibits a linear relation of shear stress (τ) to
shear rate (ϒ), and thus a constant viscosity in different environmental conditions.

Rather, the fluid precursor fit best to the non-Newtonian model known as the power
law model. This particular model is indicative of a fluid that exhibits shear-thinning, or a
pseudo-plastic behavior, which means that it has a decrease in the viscosity as it is
subjected to larger shear stresses. This shear thinning property is characteristic of the
Van der Waals and hydrogen bonds that are holding together the polymers of the
hydrogel precursor solution, due to the breaking of those weak bonds under higher
shear stresses.33 This characteristic is very important for injectable hydrogel, as this
characteristic can determine the applications that the hydrogels are capable of. For a
relevant comparison, this hydrogel was compared to PureCol®, a collagen solution
already on the market with a viscosity of 23-27 mPa*s. The viscosity of the aortic-cusp
derived hydrogel was found to be much higher at low shear stresses (76.8 mPa*s). The
shear-thinning property of this hydrogel means that this material will not be well suited
as an injectable hydrogel for drug delivery, due to its viscosity changing throughout the
injection process. When the viscosity decreases, this subjects the drug that is imbibed
to leaking out of the non-crosslinked solution prior to reaching its destination point.
However, this shear thinning characteristic is what makes this hydrogel material very
appealing for cell delivery. The viscosity coupled with the lubrication effect caused by
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the stress shearing of the hydrogel of the solution should act to shield the encapsulated
cells upon injection from the shear stresses subject to the hydrogel. This means that the
hydrogel solution should be much better at shielding the encapsulated hADSCs from the
shear stress when compared to PureCol®, theoretically resulting in a higher viability
from injection. It should be noted that this test was performed at ambient room
temperature and temperature has been shown to have an inverse effect on the viscosity
of a polymer solution.51 Ambient room temperature (≈25°C) was used for two reasons:
one, if this polymer solution is heated to >32°C then the solution will be subjected to
spontaneous gelation, and two, the injection would most likely be taking place initially
at room temperature, and therefore is a realistic representation of the application.
However, this inverse temperature dependency of viscosity means that it may be
possible to counteract this shear-thinning effect with cooling of the solution prior to
injection.
4.3 Study 3: Encapsulation of hADSCs onto different hydrogel scaffolds
Human adipose-derived stem cells were encapsulated at a density of 400,000

cells/ml onto each hydrogel and placed inside a 24-well plate, as well as using the
PureCol® hydrogel as a control and scaffolds with no cells encapsulated as the

negative control. The tracking of this contraction of the hydrogels was qualitatively

visualized over time (Figure 41, A). The AC hydrogel was found as the only hydrogel

that exhibited a contraction over a 22 day study. This contraction was found to have
a rate most closely resembling an exponential rate, as seen in Figure 41, B. The cell
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viability of the scaffold was tested and found to be viable to cells, however it was

revealed that there was not a high density of cells inside any of the 3-D constructs.

The contraction of the AC hydrogel with cells encapsulated into them prior to

plating exhibited a contraction that is indicative if a material remodeling through
cellular adhesion. This phenomena was not observed in the PureCol® hydrogel,

with or without cells. This suggests one of two possibilities: that the PureCol®, is too

dense for the cells to detach from the well-plate and therefore never contract. It

also may suggest that there are biological cues present in the AC hydrogel that are

signaling the cells to contract and remodel the hydrogel. This theory is furthered by
the collagen content of the hydrogel only making up for about 30% of the dry

weight, meaning there is probably elastin and other proteins retained from the
aortic cusp. The low density of the cells inside the 3-D constructs, shown by a
LIVE/DEAD assay, led to a further study with varying concentrations of cells,

discussed in 4.4. This live/dead assay showed decent viability, but there were not
enough cells present to draw a conclusion.
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Figure 41: Contraction comparison of different hydrogels

Figure 42: Live/Dead of contractile study
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4.4 Study 4: Hydrogel encapsulation of hADSCs in varying densities
4.4.1 Contraction of hydrogels with varying cell density
Based on the previous study, a contractile study of the AC-derived hydrogel

was used to attempt to characterize the effect of cell density on the rate of the

contraction (Figure 43, A). The rate of contraction was compared across all study
groups over a course of 12 days (Figure 43, B), upon which the highest dense

hydrogel was fully contracted and the study was stopped for viability testing. The

rate of contraction for the group seeded with 3.2 million cells/mL was graphed and
found to have a rate that seems to be trending towards an exponential rate (Figure

44, A), or otherwise has an initial surge of contraction then settling to a more linear
rate of contraction (Figure 44, B). This initial surge can be explained by the

detachment of the hydrogel from the well plate. This detachment process requires
the cells to “pull” against the matrix much more to get the hydrogel to remodel,

resulting to a higher rate initially once detachment occurs. This is further evidenced
by the initial contraction in the lower cell density hydrogels seemingly not

contracting until around day 4. This is probably how long it takes for the cells to
accumulate enough force to break the adhesion to the well plate and begin
remodeling the hydrogel.
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Figure 43: Contraction comparison of cell-encapsulated hydrogels

Figure 44: Contraction rate for cell-encapsulated hydrogels
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4.4.2 Live/Dead cytotoxicity assay
The cytoxicity of each hydrogel was concentration was assessed using a

live/dead assay (Figure 45). This assay showed there was an extremely high

number of cells that were retained on the scaffold, relative to the number of dead
cells. The viability was quantified using the live/dead images and ImageJ (NIH

freeware) to analyze the cell count of each. The viability of the AC hydrogel was
found to range between 91-95% at day 12 (Figure 46)

The live dead images in Figure 45 reveal the high viability of the hydrogel for

cell encapsulation under static seeding conditions. The Live/Dead images also

revealed an interesting tendency of the cells, which was to adhere to the edges of
the scaffold and pull the scaffold inward. This suggests that the hADSCs

encapsulated migrated to the edges of the scaffold and began the remodeling

process, which resulted in a shrunken tissue like structure. The images in at 10x

show a better view of this adherence, as the cells look as though they have stretched
out along the edges of this valve to grab the collagen fibers. The quantified viability
of 95% in the high-density seeded hydrogels, shows the extreme viability of this
hydrogel, when compared to other similar scaffolds (Figure 46) shown to have

success in hADSC encapsulation. This is probably do to the structural components

more closely resembling the native ECM, thereby keeping the cell more likely to not

initiate apoptosis. The higher density of cells also trended to a higher viability when
compared to the low density of cells (95% vs 91% viability), which suggests that the
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presence of other cells help viability and thereby suggests the initiation normal
cellular processes indicative of proper cellular function.

Figure 45: Live/Dead assay for cell encapsulation study

Figure 46: Viability analysis and comparison of various hydrogels52
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4.4.3 Biochemical analysis of cell-encapsulated hydrogels
The Glycosaminoglycan (GaGs) content was analyzed via a DMMB assay to

determine if there was a restoration of GaGs in the cell-encapsulated hydrogels. It
was found that there was a modest return of GaGs in the hydrogel, but it was not

found to be statistically significant (Figure 47). Each group was also stained for α-

smooth muscle actin (α-SMA), laminin, and vimentin using immunohistochemistry,
all proteins found in the extracellular matrix important to the cell mobility and
function (Figure 48). It should be noted that an alternative antigen retrieval

process, due to the recommended one removing the hydrogel section from the slide,
and it was very difficult to obtain a clear image as a result, and therefore are not

reliable. IHC revealed the positive stain for Vimentin across all sample, a positive
stain for α-SMA in Group B, and possibly group A. Laminin did not seem to be
positive in any of the samples.

The presence of GaGs in cell-encapsulated hydrogels and not in

decellularized cusps or non-encapsulated hydrogels, suggest that the cells are

secreting GaGs while interacting with the scaffold. This is important to note,

because the presence of GaGs is extremely integral in the tri-layered structure of the
native aortic valve, and is important in the proper lubrication of the valve. As this

study was a short term, two week study, these GaGs content would be expected to
rise over time, as the cells continue to secrete the GaGs.

A positive stain for α-SMA is characteristic of activated VICs, and a positive

stain for Vimentin is characteristic of the fibroblast phenotype. The positive stain
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on the scaffold would indicate that the presence of cells on the hydrogel results in

the differentiation into activated VICs for α-SMA and into fibroblasts for vimentin.
The protein analysis of the hydrogels seeded with ADSCs shows that there was a

positive stain for α-SMA, which is indicative of activated VICs (Figure 49). The non-

descript protein commassiee stain shows more protein than just collagen type I is
present for cell-signaling. This is extremely important for the proper cell
differentiation signaling in stem cells.

Figure 47: GAGs analysis of tissue samples
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Figure 48: Immunohistochemistry for Vimentin, Laminin, and α-Smooth Muscle Actin

Figure 49: Protein Analysis of aortic cusp derived hydrogel
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4.4.4 Electron microscopy for analysis of microstructure
The morphology of the cell-encapsulated was investigated using electron

morphology to determine the cell interactions with the extracellular matrix. SEM
was used to see the surface interactions of the cell with the collagen networks in

hydrogel (Figure 50). Adhesion interaction of the cells to the matrix was visualized,
with a specificity to the collagen, no cells were visualized binding to the elastin

presence. Globular structures were visualized on the surface of the cells. Elastin
was visualized inside the matrix morphology, further indicating the retention of

extracellular matrix components. The collagen diameter was analyzed using ImageJ
to confirm the reformation of the fibers is functional (Figure 51). The collagen
diameter formation was found to be within a range of 64-73μm, indicative of a

functional type I collagen fiber. Transmission electron microscopy was used to
visualize inside the cellular membrane (Figure 52), showing the intact cellular
components confirming the viability of these hydrogels.

The globular structures seen in Figure 50, (B and C) shows that the cell is

secreting proteins, indicating the proper functionality of these cells. These globular
structures may be the GaGs, which we found to be present in the DMMB assay, or

they could be adhesion proteins aiding in their adhesion to the extracellular matrix.
The functioning secretion of these proteins is evidence of an intact Golgi apparatus
and other cellular components important in the creation and secretion of proteins.
Further evidence of this is seen in Figure 52, with the presence of intact cellular
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components. The functional collagen diameter reformation is extremely important
to this scaffold (Figure 51), as this shows that the process of fabrication with the
pepsin breakdown does not degrade the collagen irreversibly. This leads to the

functional reformation of the collagen, and therefore a functional binding by the
hADSCs.

Figure 50: Surface morphology of cell encapsulated hydrogel
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Figure 51: Collagen fiber diameter analysis53

Figure 52: Transmission electron microscopy.
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4.5 Study 5: Injection of cell-seeded hydrogels into the base of the aortic
cusp
The injection of the encapsulated hydrogel into the base of the cusp was

investigated to determine if this scaffold would improve upon the viability that was
previously investigated by Allison Kennamer49, a former student in the BTRL. The

initial visualization of the opening and closing of the valve in the bioreactor showed
the valve to be functioning normally, meaning the injection method did not affect

functionality of the valve. Unfortunately, there was contamination after day 5 of the
study, when a leak occurred in the tubing. Figure 53 shows the H&E of the injected
cusps, which shows there are no cells present at the end of day 7, DAPI confirms
this.

This study shows how difficult it is to see cells effectively on to the aortic

cusp, as the cusp is subject to mechanical forces that wash the cells away. The

hydrogel precursor was meant to protect the encapsulated cell, but the reverse

seems to have been the case. The cells probably adhered to the hydrogel precursor,
which did not bind to the spongiosa layer of the aortic cusp upon gelation and was
washed away with the mechanical forces.

103

Figure 53: H&E and DAPI of injection study
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CHAPTER 5: CONCLUSIONS
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In cardiovascular tissue engineering, a more clinically relevant valve

replacement needs to be achieved through the full recellularization of the heart
valve scaffold. In the presented work, a new hydrogel material was developed,

optimized, and characterized to reproducibly encapsulate of stem cells inside the

scaffold. Through the analysis of the microstructure and biochemical properties of
this hydrogel, it was found that this new hydrogel scaffold has a highly viable
structure for the encapsulation of hADSCs. To support this conclusion, we

compared the viability to hydrogels already on the market in similar conditions, and
it was found to have a significantly higher viability in static conditions.
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6

CHAPTER 6: RECOMMENDATIONS FOR
FUTURE STUDIES
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6.1 Determining diffusion of cells from hydrogel
Encapsulating cells inside the hydrogel allows the cells to bind to the scaffold

and begin remodeling the hydrogel into a more tissue like structure. Due to this fact
there is the concern that the cells are content with being contained inside the

hydrogel and won’t remodel the ECM of the surrounding damaged tissue. A simple

rate of diffusion from hydrogel to a surrounding scaffold and viability test would be
sufficient to determine the effectiveness of this material as a potential material for
the delivery of cells to diseased tissue.

6.2 Viability of cells encapsulated in hydrogels: static vs. injection
It was found that this hydrogel is what is known as a shear-thinning material.

Due to this property’s presence, the cell-encapsulation capabilities of the hydrogel
may be compromised, due to the viscosity being lessened in greater shear stress.

The shear stress that is brought on by the injection through a needle may lead to the
cells on the outer parts of the hydrogel precursor diffusing out much more readily
than those hydrogels that are not subject to high shear stress prior to formation.

Also, the cells encapsulated may not be as well protected after injection compared to
prior to injection, resulting in a decrease in cell viability on the scaffold. The

hydrogel should be tested using different gauge needles to determine the optimal

needle size for retention of viability. The hydrogel should be compared to cells in
cell culture media, as well as collagen gels already on the market. When using a

material for cell delivery, the FDA requires at least 70% viability upon completion,
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so it must be determined whether this hydrogel meets these requirements postinjection.

6.3 Long term dynamic conditioning studies in the bioreactor
The initial pilot bioreactor study was only performed for a short, one week

period and only in one aortic root complex (3 cusps). Future studies should include
the preconditioning of injected valves with this cell-encapsulated hydrogel to see if

the cells differentiate into VICs under the mechanical cues of a bioreactor, while

encapsulated in the hydrogel over the course of a month long study. This should be
compared to the results of static controls, as well as to previous valve bioreactor

injection studies without the presence of the hydrogel.

The effect on the mechanics of the valve should be tested. There is a

possibility that the presence of a hydrogel could act as a reinforcement to the valve,
allowing it to further withstand the stressful environment of the cardiovascular
system. Using the Bose, or other means of fatigue testing, the valves mechanics

should be compared to that of the native valve, as well as the decellularized valve
without the hydrogel injection.

6.4 Large animal studies to determine site-specific compatibility
We have shown that this hydrogel is extremely viable for the encapsulation

of cells. In order to determine if this hydrogel can translate into in vivo environment
safely, the hydrogel should be tested in a large animal model, such as a sheep or pig,
in order to see if the hydrogel would induce an immune response, as well as to test
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to see if the stem cells would differentiate into the desired q-VIC phenotype while

inside an animal model.
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APPENDIX
Appendix A: Applications of hydrogels28
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